Methods of diagnosing als

ABSTRACT

The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/448,584, filed on Jul. 31, 2014, which is a continuation of U.S.application Ser. No. 13/313,869 (now U.S. Pat. No. 8,828,389), filed onDec. 7, 2011, which is a continuation of U.S. application Ser. No.12/792,394, filed on Jun. 2, 2010 (now U.S. Pat. No. 8,075,891), whichis a continuation of U.S. application Ser. No. 12/236,731, filed on Sep.24, 2008, (now U.S. Pat. No. 7,763,710), which is a divisional of U.S.application Ser. No. 11/367,609, filed Mar. 3, 2006 (now U.S. Pat. No.7,439,324), which is a continuation-in-part of PCT/CA2004/001503, filedAug. 20, 2004 (which designated the U.S.), which claims the benefitunder 35 USC §119 and/or 120 of U.S. provisional application Ser. No.60/496,381 (now abandoned) and Canadian application serial no.2,437,675, both filed Aug. 20, 2003, and U.S. provisional applicationSer. No. 60/497,362 (now abandoned) and Canadian application serial no.2,437,999, both filed Aug. 21, 2003, all of which are incorporatedherein by reference in their entirety.

INCORPORATION OF SEQUENCE LISTING

A computer readable form of the Sequence Listing“15289-P7643US12_Sequence_Listing.txt” (2,465 bytes), submitted viaEFS-WEB and created on Mar. 2, 2017, is herein incorporated byreference.

FIELD OF THE INVENTION

The invention relates to an epitope protection assay for use indiagnosis, prognosis and therapeutic intervention in diseases, forexample, diseases involving polypeptide aggregation such as prioninfections. The invention also relates to novel amyotrophic lateralsclerosis-specific epitopes, and their use to make novel antibodies.Further the invention includes the novel antibodies and uses thereof.

BACKGROUND OF THE INVENTION

Protein Misfolding and Aggregation

Proteins can fold into complex and close-packed structures. Folding isnot only crucial for biological activity but failure of proteins to foldproperly or remain folded can give rise to disease (Dobson C M, Methods(2004) 34:4-14). Misfolding can in some cases cause protein aggregationwhich can further give rise to discrete deposits extracellularly (e.g.,plaques) or intracellularly (e.g., inclusions in the cytosol ornucleus).

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson'sdisease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis(ALS) and prion diseases are characterized by neural deposits ofmisfolded aggregated protein. Type II diabetes and some cancers havealso been linked to protein misfolding and it is likely that there areyet to be identified diseases that result from errors in protein foldingand that in some cases lead to consequences such as aggregation. Thenature of the misfolding and any aggregation in such diseases istypically not well characterized.

Prion Diseases

Prion diseases have become a major health concern since the outbreak ofBSE or “Mad Cow Disease” (reviewed above, 40, 41). BSE was firstdiscovered in the United Kingdom but has now spread to many othercountries in Europe and Japan. In the UK alone there has been close to180,000 cases of BSE, which resulted in the destruction of cattle andpossible infection of an estimated 3-5 million head. The total costestimated to the UK was in excess of $2.5 billion. BSE is believed to betransmitted among cattle through feed that contains prions rendered frominfected cattle, and it is thought to be transmitted to humans througheating beef or other cattle products from infected animals.

Emerging Prion Diseases

The prion diseases are a group of rapidly progressive and untreatableneurodegenerative syndromes, neuropathologically characterized byspongiform change, neuronal cell loss, gliosis, and brain accumulationof abnormal amyloid polypeptide. Human prion diseases include classicalCreutzfeldt-Jakob disease (CJD), which has sporadic, iatrogenic, andfamilial forms. Since 1996, a “new variant” of CJD (vCJD) has beenidentified in the United Kingdom, France, the Republic of Ireland, HongKong, Italy, the United States, and Canada (40,41). Variant CJD iscapable of killing individuals as young as age 14 with unknownincubation period. There is little doubt that vCJD is a human form ofbovine spongiform encephalopathy (BSE)(42). The primary epidemic fromconsumption of contaminated cattle tissue has affected over 160individuals as of this initial filing.

The specter of vCJD “secondary epidemics” through blood, blood products,surgery, dentistry, vaccines, and cosmetics is of great concern (40,41).Detection of blood prion infectivity in experimental BSE/vCJD infectionsof mice and sheep (40) suggests a special risk exists for thetransmission of vCJD through blood and blood products. The recentreports of vCJD prions recipients of donors who developed the disease isalso troubling (52, 53). Canada and the United States have recentlyexpanded vCJD blood donor deferrals to all countries in Western Europe.

Although sheep scrapie has been known for centuries, the most importantanimal prion disease at present is BSE. More than 173,000 cattle,primarily from Britain, have developed symptomatic BSE, and as many as 3million have entered the food supply undetected. BSE is now beingincreasingly reported in cattle which were “born after the ban” in 1996of food supplementation with meat and bone meal, suggesting thatalternate routes may exist to keep the epidemic from being readilyextinguished. Another troubling issue is the possible transmission ofBSE to sheep, which may expose additional human populations to theBSE/vCJD prion strain. Recent reports show that prions can replicate incertain muscle groups of sheep, experimental animals and humans (54-57),indicating a potential risk in tissues previously considered safe forhuman consumption.

Chronic wasting disease (CWD) of captive and wild cervids (deer and elk)represents another newly emergent animal prion disease in North America,whose impact on human health is yet unknown. It is apparent thatnewly-recognized prion diseases pose a threat to the safety of foods,blood products, and medical-surgical treatments.

Prions: Atypical Pathogens

Newly emergent prion diseases, and the polypeptide-only nature ofprions, have created serious medical, veterinary, and economicchallenges worldwide. To date, the only commercialised tests for prioninfection have been based on post-mortem brain samples. No biochemicaltest exists to detect prions in the blood of infected animals, despitedetection by experimental transmission studies. The development ofsensitive and specific diagnostic tests for prion infection is achallenging task, in part due to the unusual nature of the prioninfectious agent. The infectious agents that transmit the prion diseasesdiffer from other pathogens in that no nucleic acid component has beendetected in infectious materials (41). According to the prion theorydeveloped by Nobel Laureate Dr. Stanley Prusiner, infectivity resides inPrP^(Sc), a misfolded conformational isoform of the near-ubiquitousnormal cellular prion polypeptide PrP^(C). FrP^(Sc) is indeed the mostprominent (or perhaps sole) macromolecule in preparations of prioninfectivity, and minimally appears to be a reliable surrogate for prioninfection. FrP^(Sc) is partially resistant to protease digestion, poorlysoluble, and exists in an aggregated state, in contrast to the proteasesensitive, soluble, monomeric isoform PrP^(C) (29, 31, 43-46).

FrP^(Sc) is derived from its normal cellular isoform (PrP^(C)), which isrich in α-helical structure, by a posttranslational process involving aconformational transition. While the primary structure of PrP^(C) isbelieved to be identical to that of PrP^(Sc), secondary and tertiarystructural changes are responsible for the distinct physicochemicalproperties of the two isoforms.

One of the difficulties in assessing the safety of food or bloodproducts from potentially infected humans with prions is the lack of anaccurate diagnostic test for blood or other accessible biosamples.Currently, there are no diagnostic tests that can be applied forscreening live animals, humans, blood or blood products at an earlystage. This also provides a further problem in organ transplantation,adding unknown risk to organ recipients. Therefore, as a preventativemeasure, countries such as the UK no longer source plasma from itsinhabitants. The risk of spreading prion diseases has affected othercountries as well. For example, the United States and Canada do notaccept blood donations from individuals who have resided in the UK orFrance for more than 3-6 months.

Currently, the diagnosis of vCJD can only be confirmed followingpathological examination of the brain at autopsy or biopsy. Somecomplimentary strategies in early CJD detection includeelectroencephalograms (EEG), magnetic resonance imaging (MRI) scans, andcerebrospinal fluid (CSF) tests, which may be useful “surrogate” or“proxy” markers. The absence of a “direct test” for prion infectionstands in stark contrast to conventional infectious agents, such asviruses and bacteria.

Some tests that are in the process of being commercialized are based onsurrogate markers of infection which are “once removed” from actualinfectious prions.

PrP protease resistance is the basis of most commercially availablediagnostic tests for prion disease. In the current methodologies, asample of brain is removed and digested with proteases that caneliminate PrP^(C), but leave a protease-resistant core of PrP^(Sc). Theprotease-resistant fragment of PrP^(Sc) is then detected byimmunoblotting (as in the Prionics test) or by capture ELISA (as in theBioRad and Enfer tests, and in a new test from Prionics). However,digestion with proteases is cumbersome and variable, leading to falsenegatives and positives. Moreover, there are some prion strains whichare reported to contain PrP^(Sc) which is infectious and aggregated, butwhich is not protease resistant. Protease-sensitive PrP^(Sc) alsopredominates early in infection and in cross-species transmission ofdisease (31).

Detection of protease-resistant PrP fragments is also the basis of aurine diagnostic test (47) which is being commercially developed byPrionics. However, detection of protease-resistant PrP in urine issubject to the same limitations as the post-mortem brain test, and hasthe additional disadvantage of requiring precipitation from largevolumes of urine, and poor sensitivity (for example, only detectingPrP^(Sc) in late stages of the disease, not pre-symptomatically).

Other Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease (AD),Huntington's disease, amyotrophic lateral sclerosis (ALS) andParkinson's disease/Lewy body dementia (PD, LBD) also pose majorchallenges to our aging population and health care system (reviewed in1). An estimated 364,000 Canadians over 65 are currently diagnosed withAD or a related dementia (http://www.alzheimer.ca/). With increased lifeexpectancy, the incidence of neurodegenerative disease is expected togrow. By 2025, AD will affect as many as a million Canadians, and by2050, this number will double.

Sporadic AD, ALS, and PD/LBD are all associated with neural accumulationof pathological multimers of misfolded polypeptides (these couldpotentially be fibrils, protofilaments, and amorphous aggregates),including the amyloid-beta (Abeta) fragment of the amyloid precursorprotein (APP) in AD; superoxide dismutase-1 (SOD1) in ALS, andalpha-synuclein in PD and LBD (1). Additionally familial amyloidoticpolyneuropathy (FAP) results from the aggregation of transthyretin toform amyloid deposits. As with prion diseases, mutations in genesencoding these polypeptides are associated with autosomal dominantfamilial forms of AD, ALS, and PD.

Alzheimer's Disease

AD is a common dementing (disordered memory and cognition)neurodegenerative disease associated with brain accumulation ofextracellular plaques composed predominantly of the Abeta (1-40), Abeta(1-42) and Abeta (1-43) peptides, all of which are proteolytic productsof APP (reviewed in 4). In addition, neurofibrillary tangles, composedprincipally of abnormally phosphorylated tau protein (a neuronalmicrotubule-associated protein), accumulate intracellularly in dyingneurons (4). Familial forms of AD can be caused by mutations in the APPgene, or in the presenilin 1 or 2 genes (www.websiteformutations.com),the protein products of which are implicated in the processing of APP toAbeta. Apolipoprotein E allelic variants also influence the age at onsetof both sporadic and familial forms of AD (reviewed in 5). Abeta hasbeen detected in the blood and CSF of AD patients and in normal controls(6). Abeta is also present in vascular and plaque amyloid filaments intrisomy 21 (Down's syndrome), hereditary cerebral hemorrhage withamyloidosis (HCHWA)-Dutch type, and normal brain aging (Mori, H et al.JBC (1992) 267: 17082-86). Tau and phosphorylated tau have been detectedin the cerebral spinal fluid (CSF) of AD patients and patients withother neurological diseases (7; reviewed in 8).

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease,with an incidence of 1 in 1000 adults, presenting as progressiveweakness, muscle atrophy, and spasticity, which is due to degenerationof ˜500,000 “lower motor neurons” in the spinal cord and brainstem, andinnumerable “upper motor neurons” in the brain cortex. An important clueto the etiology of ALS came with the finding that about 20% of familialALS (fALS) cases are due to mutations in superoxide dismutase-1 (SOD1)(10,11), a free radical defense enzyme. Over 100 fALS SOD1 missense,nonsense, and intronic splice-disrupting mutations have been cataloguedto date (12; www.alsod.org). Transgenic mice expressing mutant humanSOD1 (mtHuSOD1) develop a motor neuron syndrome with clinical andpathological similarities to human ALS (13, 14), whereas mice expressingwild-type human SOD1 (wtHuSOD1) do not develop disease (13).SOD1-containing cytoplasmic inclusions can be detected in many diseasedmotor neurons from familial and sporadic ALS patients (15), and in mosttransgenic mouse (16, 17) and tissue culture (18) models of the disease.

Parkinson's and Lewy Body Disease

PD is a neurodegenerative movement disorder second only to AD inprevalence (˜350 per 100,000 population; 1). It is clinicallycharacterized by rigidity, slowness of movement, and tremor (reviewed in21). Most cases of Parkinson's disease are sporadic, but both sporadicand familial forms of the disease are characterized by intracellularLewy bodies in dying neurons of the substantia nigra, a population ofmidbrain neurons (60,000) that are selectively decimated in PD. Lewybodies are predominantly composed of alpha-synuclein (22). Mutations inthe gene encoding alpha-synuclein have been found in patients withfamilial Parkinson's disease (reviewed in 23;www.parkinsonsmutation.com). Another gene associated with autosomalrecessive PD is parkin, which is involved in alpha-synuclein degradation(22, 23). Diffuse cortical Lewy bodies composed of alpha-synuclein areobserved in Lewy body disease (LBD), a dementing syndrome associatedwith parkinsonian tone changes, hallucinations, and rapid symptomfluctuation (24). LBD may be the second most common form ofneurodegenerative dementia after AD, accounting for 20 to 30 percent ofcases among persons over the age of 60 years (1, 24).

Huntington's Disease and Related Diseases

HD is a progressive neurodegenerative disorder characterized byexpansion of polyglutamine encoding CAG repeats in the N-terminus of thehuntingtin protein (reviewed in 48). Polyglutamine stretches of ≧36cause disease and longer repeats cause earlier onset (49, 50).

Other polyglutamine diseases such as dentate-rubral and pallido-luysianatrophy (DRPLA) and some forms of sino-cerebellar ataxia (SCA) also haveintracellular inclusions that roughly correlate to regions of neuronaldeath. Interruptions in the expanded polyglutamine repeat in the SCA-1gene product result in the absence of disease (51),

Neurodegenerative diseases, such as Alzheimer's disease (AD),amyotrophic lateral sclerosis (ALS) and Parkinson's disease/Lewy bodydisease (PD, LBD) pose major challenges to our aging population andhealth care system. No specific biochemical test exists forneurodegenerative diseases as a group (1,2). Since neurodegenerativediseases are regarded as “diagnoses of exclusion,” very broadinvestigation is required to achieve “clinically probable” diagnosis forthese progressive, incurable, and usually fatal conditions. Expensivesurrogate testing, such as neuroimaging, is utilized to increasediagnostic probability (2). The availability of specific, sensitive, andinexpensive biochemical tests for this devastating group of diseasescould potentially conserve financial resources for over-burdened healthcare systems. Moreover, secure diagnosis of these diseases at an earliersymptomatic stage increases the window for enhanced treatment efficacyat a time at which the disease pathophysiology is generally moreresponsive to treatment (3).

Effective, efficient and inexpensive diagnostic and screening strategiesfor antemortem diagnosis of human neurodegenerative diseases areurgently needed, given the aging population and continued financialpressure on the health care system.

Diabetes

Protein aggregation is also observed in patients with type II diabetes.Increased expression of the adipocyte-derived peptide, resistin, hasbeen observed in diabetes type II patients (Youn B S et al. J ClinEndocrinol Metab. (2004);89:150-6) and studies suggest that elevatedresistin levels may play a role in obesity and insulin resistance.Additionally, islet amyloid polypeptide (also known as amylin)deposition is pathogenically associated with type 2 diabetes. Thesedeposits contain islet amyloid polypeptide, a unique amyloidogenicpeptide and are associated with beta cell death. Recent studies suggestthat the species responsible for islet amyloid-induced beta-cell deathare formed early in islet amyloid formation, when islet amyloidpolypeptide accumulation begins (Hull R L et al. J Clin EndocrinolMetab. (2004) 89:3629-43). A diagnostic test that can identifypathogenic islet amyloid polypeptide would be very useful for detectingtype 2 diabetes in its early stages, when dietary and therapeuticinterventions are most effective.

Cancer

Many forms of cancer are also considered to be protein conformationdiseases (Ishimaru D. et al. Biochemistry (2003) 42:9022-7). A subset ofneuroblastomas, carcinomas and myelomas show an abnormal accumulation oftumor suppressor p53 protein aggregates (Butler J S et al. Biochemistry(2003) 42: 2396-403; Ishimaru D. et al. Biochemistry (2003) 42:9022-7).This accumulation could contribute to the loss of p53 function in somecancerous cells (Ishimaru D. et al. Biochemistry (2003) 42:9022-7).Assays able to detect accumulated p53 could provide a diagnosticallyuseful detection system and could enhance therapeutic intervention byindividualizing therapeutic intervention.

SUMMARY OF THE INVENTION

The inventor has recently developed the epitope protection assay (EPA),a novel method that yields sensitive and specific antemortem detectionof disease proteins in blood and other accessible tissues and fluids.The invention shows the role of aggregation in diseases, such as priondisease and amyotrophic lateral sclerosis, and provides an assay thatovercomes problems in the prior art. In prion diseases, the normalcellular monomeric prion polypeptide PrP^(C) undergoes refolding to anabnormal, aggregated isoform, generically designated PrP^(Sc). Diseasessuch as AD, PD, LBD, ALS and HD are also characterized by misfoldedand/or aggregated conformations of cellular proteins. This property isexploited by the methods of the invention to provide sensitive andspecific diagnostic tests for these and other diseases.

According to the invention, the methods are useful where a targetepitope is accessible in either one of a non-wildtype protein (i.e.disease protein) or a wild type protein and inaccessible in the other.Inaccessibility is often due to aggregation making the target epitopeinaccessible.

In one embodiment, the non-wildtype protein confirmation is indicativeof a disease associated with protein aggregation, such as amyotrophiclateral sclerosis.

The invention includes a method of detecting whether a candidatepolypeptide including a target epitope is a disease (disorder)polypeptide or a wild type polypeptide, comprising:

-   -   contacting the candidate polypeptide with a blocking agent; and    -   determining whether the target epitope is inacessible or        accessible to chemical modification by the blocking agent.

The accessibility or inaccessibility of the target epitope is indicativeof whether the candidate polypeptide is a disease (disorder) polypeptideor a wild type polypeptide because in one of the disease (disorder)protein and the wild type protein, the target epitope is accessible. Inthe other polypeptide the target epitope is inaccessible.

In one embodiment, the invention provides a method of detecting priondiseases, for example, determining whether a candidate polypeptideincluding a target epitope is in a wildtype conformation or in anon-wildtype conformation in which it is aggregated, comprising:

-   -   reacting a sample of polypeptide (the sample typically contains        PrP^(Sc) and/or PrP^(C), and in many cases an abundance of one        or the other) with a chemical modifying agent, typically an        agent which chemically reacts with proteins such as        peroxynitrite, which modifies accessible epitopes (target        epitopes) so that they cannot bind to a detection agent;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with detection agents, such as an antibody against a        target epitope, to determine whether the polypeptide (such as        prior to disaggregation and/or denaturing) included inaccessible        target epitopes.

PrP^(C) is rendered “invisible” in the assay, because epitopes on themonomeric molecules are blocked to antibody recognition by the chemicalmodifying agent, whereas molecules of PrP^(Sc) are “protected” fromchemical modification by virtue of being sequestered within aggregatesor otherwise unavailable for reacting. Alternatively, epitopes on themultimeric molecules are blocked to antibody recognition by the chemicalmodifying agent, whereas molecules of PrP^(C) are “protected” fromchemical modification by virtue of a difference in accessible epitopes.

In another embodiment, the Alzheimer's disease detection methodcomprises:

-   -   reacting a sample of polypeptide (the sample typically contains        all or part of diseased amyloid precursor polypeptide or A beta        or tau and/or the corresponding wild type polypeptide, and in        many cases an abundance of one or the other) with a chemical        modifying agent, typically an agent which chemically reacts with        proteins such as peroxynitrite, which modifies exposed epitopes        so that they cannot bind to a detection agent;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with detection agents, such as an antibody against a        target epitope to determine whether the polypeptide prior to        disaggregation and/or denaturing, included inaccessible target        epitopes.

In further embodiments, the invention provides disease detection methodsfor other diseases characterized by differentially accessible targetepitopes in disease and wildtype conformations, for example, resultingfrom misfolded and/or aggregated proteins such as Parkinson's disease(PD), Lewy Body disease (LBD), Huntington's disease (HD), amyotrophiclateral sclerosis (ALS), diabetes, and cancer. These methods similarlyinclude steps such as reacting a sample of polypeptide (e.g. a diseasepolypeptide described herein) with a chemical modifying agent, whichmodifies exposed epitopes so that they cannot bind to a detection agent;then disaggregating and/or denaturing the polypeptide in the sample; andprobing with detection agents, such as an antibody against a targetepitope to determine whether the polypeptide prior to disaggregationand/or denaturing, included inaccessible target epitopes. These stepsare similarly adapted for other purposes, such as screening blood andblood products, and other uses described herein.

The method of the invention has many advantages over existingtechnology. As noted above, the invention is optionally referred to as“EPA”, which in the case of prion protein disease detection is a simple,efficient method for detecting aggregated disease proteins such asPrP^(Sc), the pathogenic molecule which is thought to constitute theinfectious particle in prion diseases and Abeta peptide, associated withAD.

The invention is useful in high-throughput robotic-capable platforms.For example, EPA is not dependent on PrP protease resistance, the basisof most commercially available diagnostic tests for prion disease.Epitope protection technology does not require a protease digestionstep, which makes it more sensitive to early infection. Certainly, theabsence of a protease digestion step permits EPA to be more amenable tohigh-throughput robotic platforms.

In addition, the methods of the invention can be used to detect anyprotein that exists in two or more conformations, where one or moretarget epitopes are concealed in at least one conformation.

Accordingly, the invention relates to a detection method comprising:

-   -   reacting a sample of polypeptide with a chemical modifying        agent, typically an agent which chemically reacts with proteins,        which is defined to modify exposed epitopes so that they cannot        bind to detection agents;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with detection agents, such as antibodies against a        target epitope to determine whether the polypeptide prior to        disaggregation and/or denaturing, included target epitopes        inaccessible to the chemical modifying agent.

The result indicates whether the polypeptide includes inaccessibleepitopes, which is indicative of the type of polypeptide that is present(i.e. wild type protein or non-wild type protein).

In one embodiment, the invention includes a method of detecting whethera candidate polypeptide including a target epitope is in a wildtypeconformation or a non-wildtype conformation (in one embodiment, in thenon-wildtype conformation, the candidate polypeptide aggregates withaggregated polypeptide), comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitopes, wherein in one of        the non-wildtype conformation or the wildtype conformation, the        target epitope is accessible and reacts with the blocking agent,        and wherein in the other conformation, the target epitope is        inaccessible and does not react with the blocking agent.        Unreacted blocking agent is removed from contact with the        polypeptide, for example, by allowing time for blocking agent to        be consumed or degraded or by actively removing it by physical        or chemical processes as described below;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that prior to conversion the candidate        polypeptide was in a conformation in which the target epitope        was inaccessible and wherein lack of binding between the        detection agent and the target epitope indicates that the        polypeptide was in a conformation in which the target epitope        was accessible, thereby indicating whether the polypeptide was        in a wildtype conformation or a non-wildtype conformation.

The invention also includes a method of detecting whether a candidatepolypeptide including a target epitope is in a wildtype conformation ora non-wildtype conformation, comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the non-wildtype        conformation, the target epitope is inaccessible and does not        react with the blocking agent. Unreacted blocking agent is        removed from contact with the polypeptide, for example, by        allowing time for blocking agent to be consumed or degraded or        by actively removing it by physical or chemical processes as        described below;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and wherein lack of binding between        the detection agent and the target epitope indicates that the        polypeptide was in a wildtype conformation.

The invention also includes a method of detecting whether a candidatepolypeptide including a target epitope is in a wildtype conformation ora non-wildtype conformation, comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        non-wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the wildtype        conformation, the target epitope is inaccessible and does not        react with the blocking agent. Unreacted blocking agent is        removed from contact with the polypeptide, for example, by        allowing time for blocking agent to be consumed or degraded or        by actively removing it by physical or chemical processes as        described below;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        wildtype conformation and wherein lack of binding between the        detection agent and the target epitope indicates that the        polypeptide was in a non-wildtype conformation.

The invention also includes a method of detecting whether a candidatepolypeptide including target epitope which has been reacted with ablocking agent, is in a wildtype conformation or a non-wildtypeconformation, comprising:

-   -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope;    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and wherein lack of binding between        the detection agent and the target epitope indicates that the        polypeptide was in a wild type conformation.

In the methods of the invention, the epitope is in many casesinaccessible in the misfolded or non-wild type conformation because i)the differential misfolding of the polypeptide compared to the wild typefolded polypeptide prevents or reduces reaction between the blockingagent and the target epitope, ii) the polypeptide in the misfoldedconformation aggregates with itself or other polypeptides in themisfolded conformation to prevent or reduce reaction between theprotecting/blocking agent and the target epitope, and/or iii) posttranslational modifications of the polypeptide prevent or reducereactions between the blocking agent and the target epitope.

In one example, the candidate polypeptide comprises prion protein, thewild type folded conformation comprises the conformation of wild typefolded prion protein and the misfolded conformation comprises theconformation of PrP^(Sc). Alternatively, the wild type folded proteincomprises the conformation of APP or its cleavage product amyloid beta,and the misfolded conformation comprises the conformation of Alzheimer'sdisease APP or its cleavage product amyloid beta.

In another example, the candidate polypeptide comprises, SOD1,alpha-synuclein, islet amyloid polypeptide, resistin or p53 protein. Themethods and kits of the invention described in the application areuseful, for example, for application to a non-wildtype polypeptidehaving a conformation comprising multiple copies of a polypeptideaggregated together through interactions of beta-sheet-rich areas of thepolypeptide. In one embodiment the polypeptide is polypeptide that isaggregated in prion protein aggregates. In another embodiment, thepolypeptide is polypeptide that is aggregated in amyloid plaques.

The invention also includes i) polypeptide of the invention modified byreaction with a blocking agent listed herein and ii) the polypeptidemodified by reaction with a detecting agent. The invention also includescompositions and kits of the invention including these modifiedpolypeptide.

The blocking agent is optionally peroxynitrite, hydrogen peroxide,diethyl pyrocarbonate (DEPC), 4-hydroxynonenal (4HNE) an epoxide such asconduritol-B-epoxide and 1,2-epoxy-3-(p-nitrophenoxy)propane, methyleneor diazirine and related compounds. In the methods, the polypeptide isoptionally modified by denaturing the polypeptide, for example withheat, detergent and/or chaotropic agents. The polypeptide is optionallymodified by treatment with a disaggregation agent to disaggregate thepolypeptide from other polypeptides of the same type, and from othermolecules, wherein the disaggregation agent is optionally selected fromat least one of the group consisting of chaotropic agent (includingguanidine salts, urea or thiourea), detergent and heat.

It is readily apparent to a skilled person that the method steps of theinvention recited here involving removing the blocking agent typicallyinvolve physically, chemically or otherwise removing the blocking agentaway from the candidate polypeptide to prevent further reaction. Removaloptionally involves allowing a sufficient time to pass so that theblocking agent is removed from the candidate polypeptide by beingconsumed or degraded (for example, such that the blocking agent becomesinert or oxidized). Removal optionally involves adding a compound toreact with any excess blocking agent to inactivate it. Removal alsooptionally involves physical filtering of the blocking agent byconventional filtration techniques or centrifugation to separate thecandidate polypeptide and blocking agent, or physical binding to asubstrate useful for removing the blocking agent, such as by binding ofblocking agent or candidate polypeptide to an immobilized substrate in acolumn.

Removing means preventing further reactions by the blocking agent by,for example, physically or chemically inactivating the blocking agent,taking the blocking agent out of contact with the sample including thecandidate polypeptide or allowing a sufficient amount of time to passfor the blocking agent to be consumed or degraded.

The detection agent optionally comprises an antibody directed against aprion polypeptide epitope, an amyloid beta epitope, an alpha-synucleinepitope or a SOD1 epitope. The antibody optionally comprises all or partof the anti-prion antibodies 6H4 and 3F4, and the anti-amyloid betaantibodies 6E10 and 4G8.

The methods of the invention are preferably used with mammals, such ashumans. In addition, the methods of the invention are preferably usedwith mammals, such as livestock. In addition the methods of theinvention are used with food items, cosmetic items, dental and surgicalinstruments vacuums and pharmaceutical products.

The invention also includes a method of testing a sample from an animal,using methods of the invention described herein, to determine if theanimal has a disease characterized by the presence of candidatepolypeptide in a non-wildtype conformation in the sample, wherein thecandidate polypeptide includes a target epitope. Such diseases aredescribed herein. In one embodiment, the method comprises; determiningwhether the candidate polypeptide is in i) a wildtype conformation orii) a non-wildtype conformation, by a method comprising the steps of:

-   -   contacting the sample with a blocking agent that selectively        blocks accessible target epitope in the candidate polypeptide,        wherein in the wildtype conformation, the target epitope is        accessible and reacts with the blocking agent, and wherein in        the non-wildtype conformation, the target epitope is        inaccessible because the candidate polypeptide is aggregated        with the aggregated polypeptide and the target epitope cannot        react with the blocking agent;    -   contacting the sample with a conversion agent to modify the        candidate polypeptide to convert any inaccessible target epitope        in the sample to accessible target epitope;    -   contacting the polypeptide with a detection agent that binds        selectively to target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and the animal has a disease and        wherein lack of binding between the detection agent and the        target epitope indicates that the polypeptide was in a wild type        conformation.

The invention also includes a method of the invention described hereinfor screening, for example, by testing a sample, such as blood or bloodproducts and other samples, to determine if the sample comprises acandidate polypeptide in a non-wildtype conformation wherein thecandidate polypeptide includes a target epitope. In one embodiment, themethod comprises; determining whether the candidate polypeptide is in i)a wildtype conformation or ii) a non-wildtype conformation, by a methodcomprising the steps of:

-   -   contacting the sample with a blocking agent that selectively        blocks accessible target epitope in the candidate polypeptide,        wherein in the wildtype conformation, the target epitope is        accessible and reacts with the blocking agent, and wherein in        the non-wildtype conformation, the target epitope is        inaccessible and cannot react with the blocking agent;    -   contacting the sample with a conversion agent to modify the        candidate polypeptide to convert any inaccessible target epitope        in the sample to accessible target epitope;    -   contacting the polypeptide with a detection agent that binds        selectively to target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and the sample comprises a candidate        polypeptide in a non-wildtype conformation and wherein lack of        binding between the detection agent and the target epitope        indicates that the polypeptide was in a wild type conformation.

In another embodiment, the invention relates to a method of detectingwhether a candidate polypeptide including a target epitope is in i) awildtype conformation or ii) a non-wildtype conformation (for example,wherein the polypeptide aggregates in the non-wildtype conformation),comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the non-wildtype        conformation, the target epitope is inaccessible (for example,        because the candidate polypeptide is aggregated) and the target        epitope cannot react with the blocking agent;    -   modifying the candidate polypeptide to convert inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and wherein lack of binding between        the detection agent and the target epitope indicates that the        polypeptide was in a wild type conformation. One also removes        unreacted blocking agent from contact with the polypeptide, for        example, by allowing it to be consumed or degraded or removing        it from the reaction by physical or chemical processes.

The candidate polypeptide optionally comprises prion protein, the wildtype conformation comprises the conformation of wild type prion proteinand the non-wildtype conformation comprises the conformation ofPrP^(Sc). The candidate polypeptide optionally comprises beta-amyloidpolypeptide, tau protein or APP protein, SOD1, alpha-synuclein,huntingtin protein, p53 or islet amyloid polypeptide or resistin. Theblocking agent is optionally selected from the group consisting ofperoxynitrite, hydrogen peroxide, methylene compounds, succinicanhydride, epoxides, diethyl pyrocarbonate, 4-hydroxynonenal (4HNE) anddiazirine. The polypeptide is optionally modified by denaturing thepolypeptide. The polypeptide is also optionally denatured by heat and/ordetergent and/or chaotropic agents. The polypeptide is optionallymodified by treatment with a disaggregation agent to disaggregate thepolypeptide from the aggregated polypeptides. The disaggregation agentis optionally selected from at least one of the group consisting ofchaotropic agents, detergent and heat. The detergent optionallycomprises SDS. The detection agent optionally comprises an aptamer or anantibody, for example, directed against a prion polypeptide epitope. Theantibody optionally comprises 6H4 or 3F4. The aptamer or antibody isoptionally directed against an amyloid beta epitope. The antibodyoptionally comprises 6E10 or 4G8. The non-wildtype conformation is incertain embodiments indicative of a disease caused by proteinaggregation, such as prion disease (eg. BSE or CJD), Alzheimer'sdisease, Parkinson's disease or Lewy body disease, Huntington's disease,amyotrophic lateral sclerosis, cancer or diabetes. Optionally, prior tocontacting the blocking agent with the candidate polypeptide, thecandidate polypeptide is in a sample that is pretreated by one or moreof the following methods: adsorption, precipitation, or centrifugation.Optionally, prior to contacting the blocking agent with the candidatepolypeptide, the target epitope is mapped (ie., the epitope isidentified, for example, as described below under the “Target Epitopes”section). Optionally, the polypeptide is in a postmortem or antemortemsample selected from the group of: CSF, serum, blood, urine, biopsysample or brain tissue. Another aspect of the invention relates to a kitfor detecting whether a candidate polypeptide including a target epitopeis in i) a wildtype conformation or ii) a non-wildtype conformation,comprising a detecting agent that recognizes the target epitope andinstructions for at least one of i) mapping a target epitope, ii)contacting a candidate polypeptide with a blocking agent, and iii)contacting a candidate polypeptide with a detecting agent. The kit isuseful to implement method of the invention described herein. Thedetecting agent optionally comprises an aptamer or an antibody. Theantibody optionally comprises 6H4, 3F4, 6E10 or 4G8, optionallyimmobilized to a solid support. The kit optionally further comprisesbuffers and reagents, for example, for ELISA, such as sandwhich ELISA,fluorescent ELISA. The kit optionally further comprises a blockingagent. The kit optionally further comprises a denaturing agent selectedfrom at least one of the group of detergents and chaotropic agents. Thekit optionally further comprises a polypeptide standard. The kitoptionally comprises a recombinant disease protein or a recombinantprotein that mimics a disease protein. In another embodiment, theinvention relates to method of detecting whether a candidate polypeptidethat has been contacted with a blocking agent is i) a wildtypeconformation or ii) a non-wildtype conformation, wherein the candidatepolypeptide comprises at least one target epitope and, following contactwith the blocking agent and removal of the blocking agent, the candidatepolypeptide has been modified to convert any inaccessible target epitopeto accessible target epitope, the method comprising: contacting thepolypeptide with a detection agent that binds selectively to the targetepitope that was converted from inaccessible target epitope toaccessible target epitope, wherein binding between detection agent andconverted target epitope indicates that the candidate polypeptide was ina non-wildtype conformation (for example, an aggregated conformation)and wherein lack of binding between the detection agent and the targetepitope indicates that the polypeptide was in a wild type conformation.Diseases, blocking agents, target epitopes, detecting agents and otheraspects described herein are also useful in this method. The diseases,blocking agents, target epitopes, detecting agents and other aspectsdescribed herein are also readily adapted for the methods described inpreceding paragraphs, such as methods for testing a sample from ananimal (such as a human, livestock etc.) to determine if the animal hasa disease or screening a sample.

The reverse situation to the methods described in some of theaforementioned paragraphs is also usefully detected, for example, wherethe wildtype conformation includes an inaccessible epitope and thenon-wild type conformation has an accessible epitope. This situation isalso readily adapted to methods described herein, such as diagnosingdisease or screening samples.

The inventor has also identified and targeted ALS-specific epitopes thatare present or antibody-accessible on ALS-associated forms of SOD1, butnot on the native homodimeric form of SOD1. Such ALS-specific epitopesare those presented uniquely by the dissociated, monomeric form of SOD1,and all misfolded forms of SOD1 in monomeric, dimeric or aggregatedform, but not on the molecular surface of native dimeric forms of SOD1.These novel epitopes can be used to elicit an immune response in ananimal, for example to make antibodies specific for the epitope. Thus,the epitopes can also be defined as those epitopes that give rise toantibodies that bind selectively to the to the ALS-associated forms ofSOD1, relative to the native homodimeric form of SOD1.

Thus, the invention includes compositions for eliciting an immuneresponse in an animal comprising an effective amount of an isolatedALS-specific epitope in admixture with a suitable diluent or carrier,

wherein the ALS-specific epitope comprises an isolated peptide selectedfrom the group consisting of:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

Another aspect of the invention is a composition for eliciting an immuneresponse in an animal comprising an effective amount of a nucleic acidencoding an isolated ALS-specific epitope in admixture with a suitablediluent or carrier,

wherein the ALS-specific epitope comprises an isolated peptide selectedfrom the group consisting of:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

The invention also includes isolated antibodies made using thecompositions of the invention and antibodies specific for anALS-specific epitope, wherein the ALS-specific epitope comprises anisolated peptide selected from the group consisting of:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

A further aspect of the invention is a method for eliciting an immuneresponse in an animal using the compositions of the invention, andmethods for making antibodies using the compositions of the invention.

The antibodies of the invention can be used in EPA. Thus, one aspect ofthe invention is a method of detecting whether a candidate polypeptideincluding a target epitope is in i) a wildtype conformation or ii) anon-wildtype conformation, wherein the candidate polypeptide is SOD1,and wherein the non-wildtype conformation is an aggregated form of SOD1,comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the non-wildtype        conformation, the target epitope is inaccessible and the target        epitope cannot react with the blocking agent;    -   removing unreacted blocking agent from contact with the        polypeptide;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,    -   wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and wherein lack of binding between        the detection agent and the target epitope indicates that the        polypeptide was in a wild type conformation, and    -   wherein the detection agent comprises an antibody specific for        an ALS-specific epitope.

Another aspect of the invention is a method of detecting whether acandidate polypeptide including a target epitope is in i) a wildtypeconformation or ii) a non-wildtype conformation, comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        non-wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the wildtype        conformation, the target epitope is inaccessible and the target        epitope cannot react with the blocking agent;    -   removing unreacted blocking agent from contact with the        polypeptide;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,    -   wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        wildtype conformation and wherein lack of binding between the        detection agent and the target epitope indicates that the        polypeptide was in a non-wildtype conformation, and    -   wherein the detection agent comprises an antibody specific for a        target epitope on SOD1 that is inaccessible to blocking agent.

The antibodies specific for the ALS-specific epitope can also be used todetect ALS-associated forms of SOD1. These ALS-associated forms of SOD1present an antibody-accessible epitope that is not present on themolecular surface of native dimeric SOD1. The ALS-specific epitopes thuscan be presented by monomeric SOD1, and by misfolded SOD1 in monomeric,dimeric or aggregate form, and thereby can be used to diagnoseamyotrophic lateral sclerosis. In one embodiment of the invention, themethod includes detecting or diagnosing amyotrophic lateral sclerosis ina subject comprising the steps of:

-   -   (a) contacting a test sample of said subject with any one of the        antibodies of the invention, wherein the antibody binds to an        ALS-specific epitope to produce an antibody-antigen complex;    -   (b) measuring the amount of the antibody-antigen complex in the        test sample; and    -   (c) comparing the amount of antibody-antigen complex in the test        sample to a control        wherein a difference in the amount of antibody-antigen complex        in the test sample as compared to the control is indicative of        amyotrophic lateral sclerosis.

These antibodies can also be conjugated to labels to produce adiagnostic agent.

The invention also includes kits comprising the compositions andantibodies of the invention to elicit an immune response in an animal;or to detect monomeric or misfolded SOD1, and thereby to diagnoseamyotrophic lateral sclerosis.

Other features and advantages of the present invention will becomeapparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples while indicating preferred embodiments of the invention aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention are described in relation to the drawingsin which: FIG. 1. Brain PrP aggregated in vitro by acid treatment isprotected from modification by peroxynitrite

Mock or acid treated human brain homogenate was treated with increasingconcentrations of peroxynitrite (ONOO) and then subjected toimmunoblotting with 3F4 (panel A) or 6H4 (panel B). Effect ofperoxynitrite on the 3F4 (C) and 6H4 (D) epitope in mock (□) and acidtreated () brain homogenate. Immunoblot films were scanned and bandintensities determined by Unscanit software. The results are thecombined relative intensities of 3 separate experiments.

FIG. 2. PrP in scrapie infected hamster brain is protected frommodification by peroxynitrite

(A) Effect of peroxynitrite treatment on the 6H4 epitope in scrapieinfected hamster brain. (B) The blot in (A) was scanned and relativeband intensities determined using Unscanit software. () Scrapieinfected hamster brain. (□) Normal hamster brain.

FIG. 3 Protection from peroxynitrite induced modification is due toaggregation in acid treated brain

(A) Effect of peroxynitrite on the immunoprecipitation (IP) of PrP inmock and acid treated brain homogenate. Brain homogenate was treatedwith 10 mM peroxynitrite followed by incubation for 2 h at RT with (+)or without (−) 2.5 M guanidine hydrochloride (Gu). The resulting sampleswere immunoprecipitated with 6H4 or 3F4. More PrP is precipitated in theacid treated sample following treatment with peroxynitrite+Gu whereas inthe mock sample, Gu has no effect. This suggests that Gu is able tobreak up aggregated PrP in the acid sample that is protected fromdestruction by peroxynitrite. (B) Effect of peroxynitrite on PrP in mockand acid treated brain homogenate as measured by ELISA. Brain homogenatewas treated with increasing concentrations of peroxynitrite followed by2.5 M Gu. Following a 10-fold dilution, the samples were analyzed bysandwich ELISA with 6H4 as the capture Ab and 3F4 as the detection Ab.Similar to the immunoblot and IP data, the results show that misfoldedPrP is protected from destruction by peroxynitrite treatment, due toaggregation.

FIG. 4 Detection of aggregated amyloid beta (Abeta) using EPA

The 6E10 epitope in the Abeta region of APP is less accessible toperoxynitrite modification in Alzheimer's disease brain compared tonormal brain (panel A), and in brain homogenates that have been treatedat low pH to induce protein aggregation (panel B). Abeta 1-42 peptideaggregated in vitro shows prominent epitope protection of the 6E10epitope to peroxynitrite modification, in comparison with solublenon-aggregated Abeta 1-42 (panel C). Normal and aggregated Abeta 1-42treated with increasing concentrations of peroxynitrite and themimmunoblotted with 6E10 antibody also shows prominent epitope protection(panel D).

FIG. 5 Detection of epitopes modifiable by DEPC in SOD1

(A) Western blot showing soluble SOD1 treated with increasingconcentrations of DEPC and immunoblotted with sheep anti-SOD1. (B)Graphical representation of decreasing antibody binding to SOD1 withincreasing DEPC-concentration.

FIG. 6 Detection of aggregated alpha-synuclein using EPA

(A) Western blot showing effect of increasing concentrations of DEPC onantibody binding to soluble and insoluble alpha-synuclein. (B) Graphicalrepresentation showing the extent of antibody binding to normal (▪) andinsoluble (▴) alpha-synuclein.

DETAILED DESCRIPTION OF THE INVENTION

The current invention provides a useful method for the detection of adisease related polypeptide counterpart of a normal cellular polypeptidewhich forms aggregates or otherwise leads to the obscuration of one ormore epitopes that are not obscured in the normal or wild typepolypeptide. The invention recognizes the importance of aggregation inthe pathology of diseases such as prion disease and amyotrophic lateralsclerosis. The invention also takes advantage of this aggregation effectand provides an assay that overcomes problems with prior art detectionassays. In one embodiment, the method of the invention is applied to thedetection of PrP^(Sc) in plasma, serum, urine or other biologicalsample. The methods of the invention are further useful for detectingany polypeptide that exists in two or more conformations, where one ormore target epitopes are inaccessible in at least one conformation. Inone embodiment the invention includes a method of detecting whether acandidate polypeptide including a target epitope is in a wild type ornon-wild type conformation.

“Epitope” refers to a portion of a sequence of contiguous ornon-contiguous amino acids (antigen) which is recognized by and bound bya detection agent such as an antibody. Preferably, the epitope is alinear epitope on a polypeptide which typically includes 3 to 10 or 6 to10 or more contiguous amino acids that are recognized and bound by adetection agent. A conformational epitope includes non-contiguous aminoacids. Sometimes conformational epitopes can re-establish themselvesafter denaturation by partial refolding on, e.g, an immunoblot membrane.The detection agent such as an antibody recognizes the 3-dimensionalstructure. When a protein molecule is folded into a three dimensionalstructure the amino acids forming the epitope are positioned in a mannerthat permits the detection agent to recognize and bind to the aminoacids. In an unfolded (denatured) protein only the linear epitope isrecognized and bound by the detection agent. Since the protein isunfolded prior to contact with the detection agent, the inaccessibleepitope will typically be a linear epitope.

“Blocking agent” refers to an agent that reduces epitope reactivity, forexample by binding to the epitope or by modifying and destroying epitopereactivity, for example on an amino acid side group within a linearepitope, so that the epitope is prevented from binding to detectionagent (usually but not always an antibody). An example of a blockingagent is peroxynitrite. Other examples would include methylene, hydrogenperoxide, diethyl pyrocarbonate, 4-hydroxynonenal (4HNE) epoxides suchas conduritol-B-epoxide and 1,2-epoxy-3-(p-nitrophenoxy)propane anddiazirine. Chemical modifying agents that saturate accessible aminoacids critical for epitope recognition in native conditions are mostuseful in the applications of epitope protection technology.Additionally the blocking agent may phosphorylate, glycosylate orotherwise modify a target-epitope. The blocking agent may also includepeptides, antibodies or antibody fragments that bind to the epitope. Theblocking agent should efficiently modify accessible amino acids (e.g.modify at least: 50%, 75%, 90%, 95% or 99% of accessible amino acids).

“Accessible epitope” is target epitope that is available to react withblocking agent in methods of the invention. For example, epitope that isavailable to react with blocking agent is accessible epitope. Afterreacting with blocking agent, the accessible epitope is prevented frombinding to detection agent (after this reacting step, the reactedepitope may be referred to as the blocked epitope).

“Antibody” as used herein is intended to include monoclonal antibodies,polyclonal antibodies, and chimeric antibodies. The antibody may be fromrecombinant sources and/or produced in transgenic animals. The term“antibody fragment” as used herein is intended to include Fab, Fab′,F(ab′)₂, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, andmultimers thereof and bispecific antibody fragments. Antibodies can befragmented using conventional techniques and the fragments screened forutility in the same manner as described below. For example, F(ab′)₂fragments can be generated by treating the antibody with pepsin. Theresulting F(ab′)₂ fragment can be treated to reduce disulfide bridges toproduce Fab′ fragments. Papain digestion can lead to the formation ofFab fragments. Fab, Fab′ and F(ab′)₂, scFv, dsFv, ds-scFv, dimers,minibodies, diabodies, bispecific antibody fragments and other fragmentscan also be synthesized by recombinant techniques.

“Antibody-accessible” as used herein refers to an epitope on apolypeptide that is available to specifically bind with an antibody. Ina preferred embodiment, the novel ALS-specific epitopes areantibody-accessible on ALS-associated forms of SOD1, but not on thenative homodimeric form of SOD1.

“Aptamer” means a macromolecule such as a peptide, RNA or DNA moleculethat is able to specifically interact with a protein or peptide target.

“Inaccessible epitope” means that target epitope modification by thechemical blocking agent is prevented or significantly reduced (e.g.reduced by at least: 50%, 75%, 90%, or 95%), for example, bydifferential misfolding relative to the wild type polypeptide, byaggregation of misfolded polypeptide or by post-translationalmodifications of the polypeptide. In some cases, inaccessible epitope isconverted to accessible epitope by removing the hindrance (e.g.misfolding or aggregation) that prevents or significantly reduces targetepitope modification by the blocking agent. The inaccessible epitopethat is converted to accessible epitope may also be called “revealedepitope”.

“Detection agent” refers to an agent that binds to epitope and which maybe detected, such as antibody specific for prion polypeptide epitopesthat can be used to probe the sample containing the polypeptide. Thedetection agent is used after the polypeptide is unfolded such that thedetection preferentially binds the unblocked, unmodified epitopes.

“Disease protein or disease polypeptide” refers to a polypeptideassociated with a disease or disorder state where the modular or higherorder conformation of the polypeptide differs from the wild type ornon-disease conformation and includes mutants, variants and polymorphicversions thereof. A disease protein or disease polypeptide can also bereferred to as non-wild type conformation protein or polypeptide. Themodular conformation refers to conformational changes in the threedimensional structure of a single protein molecule. The higher orderconformation refers to conformational changes in the three dimensionalstructure of many protein molecules aggregated together. The aggregationcan consist of one or more different proteins and can be associated withnon-protein molecules. The wildtype and non-wildtype candidatepolypeptides including disease proteins or polypeptides also includerecombinant proteins, such as cellularly expressed (i.e. bacteria, usingbaculovirus sytems etc.) and in vitro translated polypeptides.

“Wildtype folded conformation” refers to the wild type, foldedconformation of protein in a non-disease or non-disorder state.

“Misfolded conformation” refers to the folded conformation ofpolypeptide in a disease or disorder state where the conformationdiffers from the wild type conformation. The difference in conformationis as a result of differential folding. The differential folding maycause protein aggregation.

“Wildtype conformation” refers to the conformation of polypeptide in itsusual or normal state or in a reference or desired state and can includepolypeptide in a non-disease or disorder state.

“Non-wildtype conformation” refers to a conformation of polypeptide thatdiffers from the conformation of the wild type polypeptide and caninclude a conformation of polypeptide in a disease or disorder, wherethe conformation differs from the wild type conformation. The differencein conformation may be as a result of differential folding, polypeptideaggregation or differential post-translational modification compared tothe wild type polypeptide. In the case of polypeptide aggregation, theaggregation may prevent accessibility of the epitope rather than thechanged conformation.

Neurodegenerative diseases, such as Alzheimer's disease (AD),amyotrophic lateral sclerosis (ALS) and Parkinson's disease/Lewy bodydementia (PD, LBD) pose major challenges to the aging population andhealth care system. No specific biochemical test exists forneurodegenerative diseases as a group (1,2). Sporadic AD, ALS, andPD/LBD are all associated with neural accumulation of pathologicalmultimers of misfolded polypeptides (such as fibrils, protofilaments,and amorphous aggregates), including the Abeta fragment of the amyloidprecursor protein (APP) in AD; superoxide dismutase-1 (SOD1) in ALS, andalpha-synuclein in PD and LBD (1). As with prion diseases, mutations ingenes encoding these aggregation-prone polypeptides are associated withautosomal dominant familial forms of AD, ALS, and PD. The detection ofdisease-associated misfolded polypeptide aggregates enables specific andsensitive antemortem diagnostic tests for neurodegenerative diseases.

To this end the inventor has invented the “epitope protection assay”(EPA), an innovative technology for detection of aggregated polypeptidesin tissues and accessible biological fluids, such as blood and CSF,which serve as “sinks” for the aggregates released from dying neurons.The method optionally consists of:

-   -   reacting a sample with a chemical modifying agent;    -   disaggregating and denaturing the treated polypeptides;    -   probing the sample with detection agents such as antibodies        against specific epitopes blocked by the chemical modifier; and    -   detection of agent-bound polypeptides (e.g., by ELISA).

Normal soluble polypeptides in the sample are rendered “invisible” inthe assay, because accessible epitopes are not detected by a detectingagent (eg. blocked to antibody recognition), whereas a proportion ofpolypeptides in aggregates are “protected” from chemical modification byvirtue of their interior sequestration, and are still available to bedetected by a detecting agent (eg. bind antibody) after disaggregation.

The methods of the invention are useful to diagnose diseasescharacterized by polypeptide misfolding and/or aggregation such as inthe diseases mentioned above or for diseases or disorders characterizedby polypeptides with otherwise differentially accessible target epitopesin disease and wildtype protein conformations.

The present inventor has also found that treatment of recombinant mouseprion polypeptide (rmPrP) at low pH in the presence of lowconcentrations of denaturants causes the polypeptide to acquireincreased beta-sheet content, reminiscent of the misfoldeddisease-associated prion polypeptide isoform, PrP^(Sc). This conversionof rmPrP is associated with increased solvent accessibility of tyrosineside chains⁴. The inventor has found that treatment of normal brainhomogenate with acid and denaturants causes PrP to become detergentinsoluble (29). In order to probe the surface accessibility of tyrosinesand other residues in normal and misfolded PrP, normal andacid-misfolded human brain tissue was treated with the chemicalnitrating compound peroxynitrite. Peroxynitrite treatment of braintissue caused a reduction in the binding of the anti-PrP antibodies 3F4and 6H4 as measured by immunoblotting, immunoprecipitation and ELISA.Peroxynitrite-induced epitope blocking was more pronounced on normalbrain PrP than on misfolded PrP, showing a protective effect ofaggregation. Similar findings were observed in normal andscrapie-infected hamster brain, in which 3F4 and 6H4 epitopes of scrapiebrain PrP were partially protected from peroxynitrite-inducedmodification. Immunoprecipitation of peroxynitrite-treated brain withanti-nitrotyrosine antibodies suggests that either PrP is nitrated ontyrosine residues or another polypeptide in proximity to PrP is nitratedand coimmunoprecipitates PrP.

Accordingly, the invention includes a method of determining polypeptideaggregation, including but not limited to PrP^(Sc), comprising:

-   -   reacting a sample with a chemical modifying agent where such        agent could be, but is not limited to, peroxynitrite    -   disaggregating and/or denaturing the chemically modified sample        with heat, detergent, or chaotropic agents; and    -   probing with antibodies specific for prion polypeptide epitopes.

The inventor has further shown that the methods of the invention areuseful for detecting Alzheimer disease proteins.

In one embodiment, the Alzheimer's disease detection method comprises:

-   -   reacting a sample of polypeptide (the sample typically contains        all or part of a disease protein or polypeptide such as amyloid        precursor polypeptide or amyloid beta or tau and/or the        corresponding wild type polypeptide, and in many cases an        abundance of one or the other) with a chemical modifying agent,        typically a blocking agent such as peroxynitrite, which modifies        exposed epitopes so that they cannot bind to a detection agent;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with detection agents, such as an antibody against a        target epitope to determine whether the polypeptide prior to        disaggregation and/or denaturing, included inaccessible target        epitopes.

Abeta containing vascular or plaque filaments are also associated withconditions such as trisomy 21 (Down's syndrome), hereditary cerebralhemorrhage with amyloidosis (HCHWA)-Dutch type, and normal brain aging(Mori, H et al. JBC (1992) 267: 17082-86). Accordingly, in oneembodiment detection of Abeta disease protein is prognostic for diseasesHCHWA-Dutch type or normal brain aging.

In addition, the methods of the invention can be combined with otherdiagnostic methods such as magnetic resonance imaging (MRI) or computedtomography (CT) scans to confirm diagnosis.

The methods of the invention are useful to detect protein or polypeptideincluding target that exists in two or more conformations, where one ormore target epitopes are concealed in at least one conformation.

Accordingly, the invention relates to a detection method comprising:

-   -   reacting polypeptide with a chemical modifying agent, typically        a blocking agent, which is defined to modify exposed epitopes so        that they cannot bind to detection agents;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with detection agents, such as antibodies against target        epitope to determine whether the polypeptide prior to        disaggregation and/or denaturing, included target epitopes        inaccessible to the chemical modifying agent.

The result indicates whether the polypeptide includes inaccessibleepitopes, which is indicative of the type of polypeptide that is present(i.e. wild type or non-wild type protein).

The invention also includes a method of detecting whether a candidatepolypeptide including a target epitope that has been reacted with ablocking agent, is in a wildtype conformation or a non-wildtypeconformation, comprising:

-   -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and wherein lack of binding between        the detection agent and the target epitope indicates that the        polypeptide was in a wild type conformation.

In another application, the invention also includes a method ofdetecting intrinsically modified polypeptide, wherein the modificationprotects target epitope from reacting with the detecting agent,comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in one of        the non-wildtype conformation or the wildtype conformation, the        target epitope is accessible and reacts with the blocking agent,        and wherein in the other conformation, the target epitope is        inaccessible and does not react with the blocking agent;    -   reacting the sample with an agent that removes the intrinsic        modification from the intrinsically modified polypeptide target        epitope;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with a detection agent, such as antibodies against the        target epitope, to determine whether the candidate polypeptide        is an intrinsically modified polypeptide.

Chemical Modifying Agents

The chemical modifying agent of the invention comprises any chemical(including a biological agent) that modifies target epitope residuessuch that the epitope is rendered invisible by the methods of theinvention (ie. not detected by the detecting agent or detection isreduced). For example, peroxynitrite preferentially modifies tyrosine,serine, methionine, histidine and tryptophan as well as cysteine andother amino acids (25, 26). DEPC preferentially modifies histidines(37), and succinic anhydride preferentially modifies residues comprisingamines. Epoxides, including conduritol-B-epoxide and1,2-epoxy-3-(p-nitrophenoxy) propane) are a reactive group used widelyfor “suicide inhibition” of carboxyl group side chains, such as thecatalytic residues of aspartyl proteases (19, 20). Hydrogen peroxide andmethylene are also useful. The chemicals may modify the target epitopeby oxidizing, nitrating, reducing, or otherwise modifying the epitope.In addition, the epitope may be modified by a chemical modifying agentthat is a phosphate group (by phosphorylation), or a gylcosyl group (bygylcosylation), and/or other chemical group that obscures the targetepitope.

Accordingly, in one embodiment the chemical modifying agent is chosenfrom the group peroxynitrite, DEPC, hydrogen peroxide, succinicanhydride, methylene and epoxides (conduritol-B-epoxide and1,2-epoxy-3-)p-nitrophenoxy)propane and/or related variants thereof.

After reacting with candidate polypeptides, the chemical modifying agentis removed. It is readily apparent to a skilled person that the methodsteps of the invention recited here involving removing the blockingagent typically involve physically, chemically or otherwise removing theblocking agent away from the candidate polypeptide to prevent furtherreaction. Removal optionally involves allowing a sufficient time to passso that the blocking agent is removed from the candidate polypeptide bybeing consumed or degraded (for example, such that the blocking agentbecomes inert or oxidized). Removal optionally involves adding acompound to react with any excess blocking agent to inactivate it.Removal also optionally involves physical filtering of the blockingagent by conventional filtration techniques or centrifugation toseparate the candidate polypeptide and blocking agent, or physicalbinding to a substrate useful for removing the blocking agent, such asby binding of blocking agent or candidate polypeptide to an immobilizedsubstrate in a column.

Removing means preventing further reactions by the blocking agent by,for example, physically or chemically inactivating the blocking agent,taking the blocking agent out of contact with the sample including thecandidate polypeptide or allowing a sufficient amount of time to passfor the blocking agent to be consumed or degraded.

Chemical modification of a target epitope leads to obscuration of anepitope to antibody recognition. In one embodiment treatment with ablocking agent such as peroxynitrite leads to destruction of epitopes onmonomeric proteins but not epitopes on aggregated proteins such asnon-wild type polypeptides or disease proteins.

Pretreatment

The methods of the invention also contemplate pretreatment of the sampleto enhance EPA detection. For example if decreased detection ofaggregated proteins such as prions in blood or urine is observed,pre-clearing strategies are readily employed to enhance detection withdetergents, precipitating agents, and adsorbents such as those typicallyused in commercial ELISA assays which are known to one skilled in theart. Polypeptide samples may also be pretreated with agents such asdetergents or guanidine or heat. Finally samples may be concentrated orprecleared by methods such as centrifugation. Accordingly, in oneembodiment the samples are pretreated before employing a method of theinvention.

Detecting Misfolded or Aggregated Proteins and Polypeptides The inventorhas found a method that detects polypeptides that have target epitopesthat are accessible to detection in one conformation and inaccessible inanother by modification of inaccessible epitopes by a modifying agent.The inventor has identified several epitopes that are useful as targetepitopes in the methods of the invention. Other target epitopes areidentified as described below.

Target Epitopes

Target epitopes are identified for polypeptides that exist in two ormore conformations wherein epitopes that can be detected by detectingagents such as antibodies, aptamers or peptides, are accessible in oneconformation and inaccessible in the other conformation. Where anepitope is found to be blocked from detection by a blocking agent in oneconformation of the polypeptide, the epitope is a target epitope. Toidentify target epitopes, a detection agent such as an antibody ischosen. If the detection agent is an antibody it is preferably amonoclonal antibody although polyclonal antibodies are also usable. Theepitope, which can be a linear or non-linear epitope, and which isspecifically recognized by the antibody, is optionally a known epitope.A candidate chemical modifying agent such as peroxynitrate is chosen. Ifthe epitope recognized by the detection agent is known, the candidatechemical modifying agent is preferably chosen based on its ability tomodify amino acid residues in the target epitope. For exampleperoxynitrite preferentially modifies tyrosine and histidine residueswith some modification of cysteine and other amino acids. Peroxynitriteis optionally chosen as chemical modifying agent if tyrosines and/orhistidines are present in the target epitope. Aliquots of a samplecomprising wild type polypeptide and aliquots of a sample comprisingnon-wildtype polypeptide are reacted with increasing concentrations ofthe chosen chemical modifying agent. Each sample comprises one or moreof recombinant polypeptide, cell extracts or tissue samples known toexpress the polypeptide in either the wild type or non-wild typeconformation. Preferably samples of polypeptide have similarconcentrations of polypeptide. The non-wildtype conformation polypeptidesample is alternatively obtained by treating a polypeptide in wild typeconformation with an agent, such as acid, that induces conversion to anon-wildtype conformation.

Each sample of polypeptide is denatured and/or disaggregated to convertany inaccessible putative target epitope to accessible target epitope.Each sample of polypeptide is then contacted with the chosen detectionagent. Detection is performed using techniques known in the art such asELISA, and Western blotting. The amount of signal generated by thedetection agent for sample comprising polypeptide in a wildtypeconformation treated with protection agent and for sample comprisingpolypeptide in a non-wildtype conformation treated with protection agentare compared. A difference in detection at one or more concentrations ofchemical modifying agent indicates that the epitope is protected in oneconformation and further indicates that the epitope is a target epitope.A difference over a range of chemical modifying agent concentrationsindicates that the target epitope is useful for EPA. The process isrepeated with different blocking agents and/or detecting agents andtarget epitopes are identified. One typically standardizes and titratesthe blocking agent and to performs experiments using a “universal”chemical modifier such as methylene^(24,25), which optionally yieldsmore uniform and complete protection of the target epitope.

Accordingly in one example, a method of identifying a target epitope ina polypeptide that has two or more conformations wherein the targetepitope is accessible to detection in one conformation and inaccessiblein another conformation comprises:

-   -   reacting a sample comprising polypeptide in a wild type        conformation and a sample comprising polypeptide in a non-wild        type conformation typically with one or more concentrations of a        chemical modifying agent;    -   denaturing and/or disaggregating each sample to convert any        inaccessible target epitope to accessible target epitope;    -   contacting the samples with a detection agent; and    -   comparing the signal generated by the detection agent for        samples comprising polypeptide in a wildtype conformation        treated with chemical modifying agent and for samples comprising        polypeptide in a non-wildtype conformation treated with chemical        modifying agent wherein a difference in detection between sample        comprising wildtype polypeptide and sample comprising non-wild        type sample indicates that the epitope is protected in one        conformation and further indicates that the epitope is a target        epitope.

ALS-Specific Epitopes

The inventor provides unique “ALS-specific epitopes” presented by orantibody-accessible on monomeric or misfolded forms of SOD1 inmonomeric, dimeric or aggregate form, but not on the native homodimericform of SOD1. The following 2 epitopes have been identified by theinventor as ALS-specific epitopes:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

A person skilled in the art will appreciate that the ALS-specificepitope can be all or part of the above sequences. The term “part of” asused herein refers to the sequence that retains the epitope activity foreliciting an immune response in an animal. The invention also includesvariants of the above sequences.

The term “variant” as used herein includes modifications or chemicalequivalents of the amino acid and nucleotide sequences of the presentinvention that perform substantially the same function as the proteinsor nucleic acid molecules of the invention in substantially the sameway. For example, variants of proteins of the invention include, withoutlimitation, conservative amino acid substitutions. Variants of proteinsof the invention also include additions and deletions to the proteins ofthe invention. In addition, variant peptides and variant nucleotidesequences include analogs and derivatives thereof.

A “conservative amino acid substitution”, as used herein, is one inwhich one amino acid residue is replaced with another amino acid residuewithout abolishing the peptide's desired properties.

The term “derivative of a peptide” refers to a peptide having one ormore residues chemically derivatized by reaction of a functional sidegroup. Such derivatized molecules include for example, those moleculesin which free amino groups have been derivatized to form aminehydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups,t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Freecarboxyl groups may be derivatized to form salts, methyl and ethylesters or other types of esters or hydrazides. Free hydroxyl groups maybe derivatized to form O-acyl or O-alkyl derivatives. The imidazolenitrogen of histidine may be derivatized to form N-im-benzylhistidine.Also included as derivatives are those peptides which contain one ormore naturally occurring amino acid derivatives of the twenty standardamino acids. For examples: 4-hydroxyproline may be substituted forproline; 5-hydroxylysine may be substituted for lysine;3-methylhistidine may be substituted for histidine; homoserine may besubstituted for serine; and ornithine may be substituted for lysine.

The peptides constituting these epitopes can further comprise additionalamino acid residues particularly at the N- and C-terminal flanksthereof, which may be useful in conjugating the epitope with an agentuseful for instance in eliciting an immune response, or an agent servingas a tag useful in the production of the epitope or to monitor itspresence. For instance, the epitope may further comprise an N-terminalCys residue to assist with coupling to KLH or the like. The epitope mayfurther comprise a linker effective to couple the epitope tandemly toanother copy of the same or a different epitope. Alternatively, theepitope may further comprise a polyhistidine or Flag tag, In anotherembodiment, the epitopes may comprise additional amino acids thatenhance the immunogenecity or solubility of the epitope. In oneembodiment, the additional amino acids number from 1 to about 10,preferably 1 to 8, more preferably 1 to 5. Importantly the additionalresidues do not materially affect the conformation of the epitope.

In one embodiment of the invention, the variant amino acid sequence hasat least 70% sequence identity, preferably at least 80% sequenceidentity, more preferably at least 90% sequence identity to the abovesequences (SEQ ID:1 and SEQ ID NO:2). The term “sequence identity” asused herein refers to the percentage of sequence identity between twopolypeptide sequences. In order to determine the percentage of identitybetween two polypeptide sequences, the amino acid sequences of such twosequences are aligned, preferably using the Clustal W algorithm(Thompson, J D, Higgins D G, Gibson T J, 1994, Nucleic Acids Res. 22(22): 4673-4680), together with BLOSUM 62 scoring matrix (Henikoff S.and Henikoff J. G., 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919)and a gap opening penalty of 10 and gap extension penalty of 0.1, sothat the highest order match is obtained between two sequences whereinat least 50% of the total length of one of the sequences is involved inthe alignment. Other methods that may be used to align sequences are thealignment method of Needleman and Wunsch (J. Mol. Biol., 1970, 48: 443),as revised by Smith and Waterman (Adv. Appl. Math., 1981, 2: 482) sothat the highest order match is obtained between the two sequences andthe number of identical amino acids is determined between the twosequences. Other methods to calculate the percentage identity betweentwo amino acid sequences are generally art recognized and include, forexample, those described by Carillo and Lipton (SIAM J. Applied Math.,1988, 48:1073) and those described in Computational Molecular Biology,Lesk, e.d. Oxford University Press, New York, 1988, Biocomputing:Informatics and Genomics Projects. Generally, computer programs will beemployed for such calculations. Computer programs that may be used inthis regard include, but are not limited to, GCG (Devereux et al.,Nucleic Acids Res., 1984, 12: 387) BLASTP, BLASTN and FASTA (Altschul etal., J. Molec. Biol., 1990: 215: 403).

A person skilled in the art will appreciate that there may be otherALS-specific epitopes. For example, other disease specific epitopes maybe identified using the epitope protection assay described in herein. Inanother example, other disease specific epitopes may be identified usingthe method disclosed in Khare et al.

(Proteins: Structure, Function and Bioinformatics (2005) 61:617-632).Furthermore, useful epitopes can be identified as those presentinguniquely in SOD1 that is acidified, or otherwise treated to induceadoption of a monomeric or misfolded conformation, relative to a pHneutral control SOD1.

Conditions for EPA

Titration experiments with peroxynitrite, hydrogen peroxide andmethylene (based on UV light photolysis of the precursor diazirine) orother modifying agents, are useful to improve conditions for epitopeprotection.

Samples known to contain polypeptides in two or more conformations,including disease proteins, are optionally reacted using immunoblottingand ELISA. In each case, samples are prepared and optionally mixed withincreasing concentrations of the modifying agent and processed, forexample, by immunoblotting, ELISA and/or time resolved fluorescence.This defines the type and concentration of chemical agent allowing themaximal distinction between monomeric and aggregated proteins includingdisease proteins. Additional informative experiments can involve usingrecombinant disease (non-wild type) protein (such as acid treated prionproteins or mutant p53 proteins and other protein listed in thisapplication) and normal (wild type) protein in place of samplescontaining disease proteins.

In some cases, disease proteins may have different properties forchemical modification than do recombinant disease proteins, and diseaseproteins in one sample type (such as brain tissue) may display differentchemical modification properties than disease proteins circulating inblood, or detectable in urine. One of skill in the art shall readilyidentify the optimal conditions for endogenous prions using knowntechniques.

The EPA achieves superior commercial utility by detecting diseaseproteins in biological tissues and fluids for which no presenttechnology exists. Some disease proteins are in very low abundance. Forexample prions are in very low abundance (10-100 prions/mL by bioassay),and protease-resistant PrP in urine is only intermittently/sporadicallydetectable by precipitation of large fluid volumes. Also, anyprospective blood test must contend with high concentrations of wildtypeprotein (i.e. for PrP^(C) (typically 10⁶-fold more than PrP^(Sc))) and“blocking” by heterologous plasma proteins. Using the optimized chemicalmodification regimen and the DELFIA-TRF system, the sensitivitythresholds for EPA in blood and urine are optionally determined using:

-   -   1. Animal and human plasma and urine “spiked” with a titration        of disease protein;    -   2. Plasma and urine from model disease animals expressing a        disease protein.

Biological fluids clinically accessible by non-invasive routes provide asubstrate for a practical antemortem test for diagnosis and screening ofdiseases involving aggregated disease proteins in humans and animals.The methods of this invention are also useful in post-mortem testing.One of skill in the art readily determines whether EPA with “diseaseprotein spike” titration in normal blood and urine reveals similarDELFIA-TRF signals to the same disease protein titration in buffer,showing that the EPA is not affected by “blocking factors” in thesebiological fluids. Preferential “blocking” of disease protein byheterologous proteins may actually enhance epitope protection tochemical modifying agents. If decreased detection of disease protein inblood or urine is observed, pre-clearing strategies are readily employedto enhance disease protein detection, for example, with detergents,precipitating agents, and adsorbents typically used in commercial ELISAassays which are known to one skilled in the art.

In one embodiment, the methods of the invention involve the detection oftarget epitopes in misfolded or aggregated polypeptides. In anotherembodiment, the invention provides a method for improving or optimizingthe detection of polypeptides that can exist in 2 or more conformations.In another embodiment the detection of misfolded and/or aggregatedpolypeptides is indicative of disease (disease proteins). In anotherembodiment, polypeptides are detected using detection agents such asantibodies, aptamers or peptides that specifically bind to epitopes ofpolypeptides that can be chemically modified. In another embodimentthese polypeptides are disease proteins. Antibodies to candidate proteinepitopes are commercially available antibodies or are readily preparedby a person skilled in the art and include antibody fragments, andsingle chain antibodies. All the aforementioned methods are readilyimplemented using steps described in this application.

Antibodies

The invention contemplates the use of known antibodies as the bindingagent including biotin-3F4 and 3F4 and 6H4 which recognize prion diseaseproteins. 3F4 reacts against the MKHM (SEQ ID NO:3) epitope and 6H4reacts against the DYEDRYYRE (SEQ ID NO:4) epitope. Additionally, 6E10which recognizes Abeta, reacts against the EFRHDS (SEQ ID NO:5) epitope(residues 3-8).

Other antibodies and the epitopes recognized (if known) which areoptionally used with the methods of the invention are listed in thetable below.

TABLE Antibodies useful to detect disease proteins Protein AntibodyMono/Poly Epitope Company Abeta 4G8 Monoclonal Within aa18-22 of humanAbeta Signet 6E10 Monoclonal Within aa3-8 of human Abeta Signet ab2539Polyclonal NA Abcam Abeta-NT Polyclonal NA QED Bioscience DE2B4Monoclonal Within aa1-17 of human Abeta Acris antibodies NBA-104EMonoclonal Within aa1-16 of human Abeta Stressgen Alpha- 4D6 MonoclonalUnknown Acris antibodies synuclein ab6162 Polyclonal NA Abcam LB509Monoclonal Unknown Zymed Syn-1 Monoclonal Within aa91-99 of human a-synBD Biosciences Syn-204 Monoclonal Within aa87-110 of human a- Lab Visionsyn Syn-211 Monoclonal Within aa121-125 of human a- Lab Vision syn TauMouse Anti-Tau-1 Monoclonal Within aa95-108 of human tau Biomeda MouseAnti-Tau-2 Monoclonal Unknown Stressgen T14 Monoclonal Within aa141-178of human tau Zymed T46 Monoclonal Within aa404-441 of human tau ZymedTau-2 Monoclonal Unknown Acris antibodies Tau-5 (ab3931) MonoclonalUnknown Abcam SOD1 Mouse SOD1 Monoclonal Unknown Sigma-aldrich RabbitSOD1 Polyclonal Unknown Stressgen Rat SOD1 Polyclonal Unknown StressgenSheep SOD1 Polyclonal Unknown OxisResearch

The invention also includes isolated antibodies to the novelALS-specific epitopes disclosed herein, and compositions and methods formaking the antibodies. For example these novel epitopes can be used toelicit an immune response in an animal, for example to make antibodiesspecific for the epitope. The phrase “eliciting an immune response” isdefined as initiating, triggering, causing, enhancing, improving oraugmenting any response of the immune system, for example, of either ahumoral or cell-mediated nature. The initiation or enhancement of animmune response can be assessed using assays known to those skilled inthe art including, but not limited to, antibody assays (for exampleELISA assays), antigen specific cytotoxicity assays and the productionof cytokines (for example ELISPOT assays).

Thus, the invention includes compositions for eliciting an immuneresponse in an animal comprising an effective amount of an isolatedALS-specific epitope in admixture with a suitable diluent or carrier,

wherein the ALS-specific epitope comprises an isolated peptide selectedfrom the group consisting of:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

The term “animal” as used herein includes all members of the animalkingdom including mammals, and preferably includes animals capable ofmaking antibodies.

Immunogenicity can be significantly improved if the immunizing agent(s)(e.g. isolated ALS-specific epitope) and/or composition is, regardlessof administration format, co-immunized with an adjuvant. Commonly,adjuvants are used as in 0.05 to 1.0 percent solution in phosphatebuffered saline. Adjuvants enhance the immunogenicity of an immunogenbut are not necessarily immunogenic themselves. Adjuvants may act byretaining the immunogen locally near the site of administration toproduce a depot effect facilitating a slow, sustained release ofimmunogen to cells of the immune system. Adjuvants can also attractcells of the immune system to an immunogen depot and stimulate suchcells to elicit immune responses. As such, embodiments of this inventionencompass compositions further comprising adjuvants.

Adjuvants have been used for many years to improve the host immuneresponses to, for example, vaccines. Intrinsic adjuvants (such aslipopolysaccharides) normally are the components of killed or attenuatedbacteria used as vaccines. Extrinsic adjuvants are immunomodulatorswhich are typically non-covalently linked to antigens and are formulatedto enhance the host immune responses. Thus, adjuvants have beenidentified that enhance the immune response to antigens deliveredparenterally. Some of these adjuvants are toxic, however, and can causeundesirable side-effects making them unsuitable for use in humans andmany animals. Indeed, only aluminum hydroxide and aluminum phosphate(collectively commonly referred to as alum) are routinely used asadjuvants in human and veterinary vaccines. The efficacy of alum inincreasing antibody responses to diphtheria and tetanus toxoids is wellestablished. Notwithstanding, it does have limitations. For example,alum is ineffective for influenza vaccination and inconsistently elicitsa cell mediated immune response with other immunogens. The antibodieselicited by alum-adjuvanted antigens are mainly of the IgG1 isotype inthe mouse, which may not be optimal for protection by some vaccinalagents.

A wide range of extrinsic adjuvants can provoke potent immune responsesto immunogens. These include saponins complexed to membrane proteinantigens (immune stimulating complexes), pluronic polymers with mineraloil, killed mycobacteria and mineral oil, Freund's complete adjuvant,bacterial products such as muramyl dipeptide (MDP) andlipopolysaccharide (LPS), as well as lipid A, and liposomes.

In one aspect of this invention, adjuvants useful in any of theembodiments of the invention described herein are as follows. Adjuvantsfor parenteral immunization include aluminum compounds (such as aluminumhydroxide, aluminum phosphate, and aluminum hydroxy phosphate). Theantigen can be precipitated with, or adsorbed onto, the aluminumcompound according to standard protocols. Other adjuvants such as RIBI(ImmunoChem, Hamilton, Mont.) can also be used in parenteraladministration.

Adjuvants for mucosal immunization include bacterial toxins (e.g., thecholera toxin (CT), the E. coli heat-labile toxin (LT), the Clostridiumdifficile toxin A and the pertussis toxin (PT), or combinations,subunits, toxoids, or mutants thereof). For example, a purifiedpreparation of native cholera toxin subunit B (CTB) can be of use.Fragments, homologs, derivatives, and fusion to any of these toxins arealso suitable, provided that they retain adjuvant activity. Preferably,a mutant having reduced toxicity is used. Suitable mutants have beendescribed (e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627(Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PTmutant)). Additional LT mutants that can be used in the methods andcompositions of the invention include, for example Ser-63-Lys,Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants (suchas a bacterial monophosphoryl lipid A (MPLA) of various sources (e.g.,E. coli, Salmonella minnesota, Salmonella typhimurium, or Shigellaflexneri, saponins, or polylactide glycolide (PLGA) microspheres) canalso be used in mucosal administration.

Adjuvants useful for both mucosal and parenteral immunization includepolyphosphazene (for example, WO 95/2415), DC-chol (3b-(N-(N′,N′-dimethyl aminomethane)-carbamoyl) cholesterol (for example,U.S. Pat. No. 5,283,185 and WO 96/14831) and QS-21 (for example, WO88/9336).

The immunogenicity or effectiveness of the composition to treatamyotrophic lateral sclerosis or elicit an immune response can also beenhanced by conjugating the isolated ALS-specific epitope to a moleculethat enhances the immunogenicity of the epitope. For example, theALS-specific epitope can be conjugated to keyhole limpet hemocyanin(KLH). KLH is a respiratory protein found in mollusks. Its large sizemakes it very immunogenic, and the large number of lysine residuesavailable for conjugation make it very useful to attach to an protein,such as an isolated ALS-specific epitope.

The ALS-specific epitopes may be prepared using a variety of methodsknown to one skilled in the art. Accordingly, ALS-specific epitopes maybe prepared by chemical synthesis using techniques well known in thechemistry of proteins such as solid phase synthesis (Merrifield, J. Am.Chem. Assoc. 85:2149-2154 (1964)) or synthesis in homogenous solution(Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15, pts.I and II, Thieme, Stuttgart (1987)).

The ALS-specific epitopes may also be produced by recombinant DNAtechnology. To prepare the ALS-specific epitopes by recombinant DNAtechniques, a DNA sequence encoding the ALS-specific epitopes must beprepared. Consequently, the present invention also includes the use ofpurified and isolated nucleic acids comprising a nucleotide sequencecoding for ALS-specific epitopes to elicit an immune response.

In one embodiment the nucleic acid sequence encoding the ALS-specificepitopes is incorporated into an expression vector adapted fortransfection or transformation of a host cell. The nucleic acidmolecules may be incorporated in a known manner into an appropriateexpression vector which ensures expression of the protein. Possibleexpression vectors include but are not limited to cosmids, plasmids, ormodified viruses (e.g. replication defective retroviruses, adenovirusesand adeno-associated viruses). The vector should be compatible with thehost cell used. The expression vectors are “suitable for transformationof a host cell”, which means that the expression vectors contain anucleic acid molecule encoding the ALS-specific epitopes and regulatorysequences selected on the basis of the host cells to be used forexpression, which is operatively linked to the nucleic acid molecule.“Operatively linked” is intended to mean that the nucleic acid is linkedto regulatory sequences in a manner which allows expression of thenucleic acid.

Suitable regulatory sequences may be derived from a variety of sources,including bacterial, fungal, viral, mammalian, or insect genes (Forexample, see the regulatory sequences described in Goeddel, GeneExpression Technology: Methods in Enzymology 185, Academic Press, SanDiego, Calif. 1990). Selection of appropriate regulatory sequences isdependent on the host cell chosen as discussed below, and may be readilyaccomplished by one of ordinary skill in the art. Examples of suchregulatory sequences include: a transcriptional promoter and enhancer orRNA polymerase binding sequence, a ribosomal binding sequence, includinga translation initiation signal. Additionally, depending on the hostcell chosen and the vector employed, other sequences, such as an originof replication, additional DNA restriction sites, enhancers, andsequences conferring inducibility of transcription may be incorporatedinto the expression vector.

The recombinant expression vectors may also contain a marker gene whichfacilitates the selection of host cells transformed or transfected witha recombinant molecule of the invention. Examples of selectable markergenes are genes encoding a protein such as G418 and hygromycin whichconfer resistance to certain drugs, β-galactosidase, chloramphenicolacetyltransferase, firefly luciferase, or an immunoglobulin or portionthereof such as the Fc portion of an immunoglobulin preferably IgG.Transcription of the selectable marker gene is monitored by changes inthe concentration of the selectable marker protein such asβ-galactosidase, chloramphenicol acetyltransferase, or fireflyluciferase. If the selectable marker gene encodes a protein conferringantibiotic resistance such as neomycin resistance transformant cells canbe selected with G418. Cells that have incorporated the selectablemarker gene will survive, while the other cells die. This makes itpossible to visualize and assay for expression of recombinant expressionvectors of the invention and in particular to determine the effect of amutation on expression and phenotype. It will be appreciated thatselectable markers can be introduced on a separate vector from thenucleic acid of interest.

Recombinant expression vectors can be introduced into host cells toproduce a transformant host cell. The term “transformant host cell” isintended to include prokaryotic and eukaryotic cells which have beentransformed or transfected with a recombinant expression vector encodingthe ALS-specific epitopes. The terms “transformed with”, “transfectedwith”, “transformation” and “transfection” are intended to encompassintroduction of nucleic acid (e.g. a vector) into a cell by one of manypossible techniques known in the art. Prokaryotic cells can betransformed with nucleic acid by, for example, electroporation orcalcium-chloride mediated transformation. Nucleic acid can be introducedinto mammalian cells via conventional techniques such as calciumphosphate or calcium chloride co-precipitation, DEAE-dextran mediatedtransfection, lipofectin, electroporation or microinjection. Suitablemethods for transforming and transfecting host cells can be found inSambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition,Cold Spring Harbor Laboratory press (1989)), and other laboratorytextbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotichost cells. For example, the proteins of the invention may be expressedin bacterial cells such as E. coli, insect cells (using baculovirus),yeast cells or mammalian cells. Other suitable host cells can be foundin Goeddel, Gene Expression Technology: Methods in Enzymology 185,Academic Press, San Diego, Calif. (1991).

More particularly, bacterial host cells suitable for carrying out thepresent invention include E. coli, B. subtilis, Salmonella typhimurium,and various species within the genus Pseudomonas, Streptomyces, andStaphylococcus, as well as many other bacterial species well known toone of ordinary skill in the art. Suitable bacterial expression vectorspreferably comprise a promoter which functions in the host cell, one ormore selectable phenotypic markers, and a bacterial origin ofreplication. Representative promoters include the β-lactamase(penicillinase) and lactose promoter system (see Chang et al., Nature275:615 (1978)), the trp promoter (Nichols and Yanofsky, Meth. inEnzymology 101:155, 1983) and the tac promoter (Russell et al., Gene 20:231, 1982). Representative selectable markers include various antibioticresistance markers such as the kanamycin or ampicillin resistance genes.Suitable expression vectors include but are not limited tobacteriophages such as lambda derivatives or plasmids such as pBR322(see Bolivar et al., Gene 2:9S, (1977)), the pUC plasmids pUC18, pUC19,pUC118, pUC119 (see Messing, Meth in Enzymology 101:20-77, 1983 andVieira and Messing, Gene 19:259-268 (1982)), and pNH8A, pNH16a, pNH18a,and Bluescript M13 (Stratagene, La Jolla, Calif.). Typical fusionexpression vectors which may be used are discussed above, e.g. pGEX(Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly,Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.). Examples of induciblenon-fusion expression vectors include pTrc (Amann et al., Gene69:301-315 (1988)) and pET 11d (Studier et al., Gene ExpressionTechnology: Methods in Enzymology 185, Academic Press, San Diego,Calif., 60-89 (1990)).

Yeast and fungi host cells suitable for carrying out the presentinvention include, but are not limited to Saccharomyces cerevisiae,Schizosaccharomyces pombe, the genera Pichia or Kluyveromyces andvarious species of the genus Aspergillus. Examples of vectors forexpression in yeast S. cerivisiae include pYepSec1 (Baldari. et al.,Embo J. 6:229-234 (1987)), pMFa (Kurjan and Herskowitz, Cell 30:933-943(1982)), pJRY88 (Schultz et al., Gene 54:113-123 (1987)), and pYES2(Invitrogen Corporation, San Diego, Calif.). Protocols for thetransformation of yeast and fungi are well known to those of ordinaryskill in the art (see Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929(1978); Itoh et al., J. Bacteriology 153:163 (1983), and Cullen et al.(Bio/Technology 5:369 (1987)).

Mammalian cells suitable for carrying out the present invention include,among others: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g. ATCC No.CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCCNo. 1573) and NS-1 cells. Suitable expression vectors for directingexpression in mammalian cells generally include a promoter (e.g.,derived from viral material such as polyoma, Adenovirus 2,cytomegalovirus and Simian Virus 40), as well as other transcriptionaland translational control sequences. Examples of mammalian expressionvectors include pCDM8 (Seed, B., Nature 329:840 (1987)) and pMT2PC(Kaufman et al., EMBO J. 6:187-195 (1987)).

Given the teachings provided herein, promoters, terminators, and methodsfor introducing expression vectors of an appropriate type into plant,avian, and insect cells may also be readily accomplished. For example,within one embodiment, the proteins of the invention may be expressedfrom plant cells (see Sinkar et al., J. Biosci (Bangalore) 11:47-58(1987), which reviews the use of Agrobacterium rhizogenes vectors; seealso Zambryski et al., Genetic Engineering, Principles and Methods,Hollaender and Setlow (eds.), Vol. VI, pp. 253-278, Plenum Press, NewYork (1984), which describes the use of expression vectors for plantcells, including, among others, pAS2022, pAS2023, and pAS2034).

Insect cells suitable for carrying out the present invention includecells and cell lines from Bombyx or Spodotera species. Baculovirusvectors available for expression of proteins in cultured insect cells(SF 9 cells) include the pAc series (Smith et al., Mol. Cell Biol.3:2156-2165 (1983)) and the pVL series (Lucklow, V. A., and Summers, M.D., Virology 170:31-39 (1989)). Some baculovirus-insect cell expressionsystems suitable for expression of recombinant proteins are described inPCT/US/02442.

The recombinant expression vectors containing the nucleotide sequencesencoding the ALS-specific epitopes may also contain genes which encode afusion moiety (i.e. a “fusion protein”) which provides increasedexpression of the recombinant peptide; increased solubility of therecombinant peptide; and aid in the purification of the targetrecombinant peptide by acting as a ligand in affinity purification. Forexample, a proteolytic cleavage site may be added to the targetrecombinant protein to allow separation of the recombinant protein fromthe fusion moiety subsequent to purification of the fusion protein.Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne,Australia), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5(Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase(GST), maltose E binding protein, or protein A, respectively, to therecombinant protein

Another aspect of the invention is a composition for eliciting an immuneresponse in an animal comprising an effective amount of a nucleic acidencoding an isolated ALS-specific epitope in admixture with a suitablediluent or carrier,

wherein the ALS-specific epitope comprises an isolated peptide selectedfrom the group consisting of:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

In embodiments, nucleic acids encoding the misfolded SOD1-specificepitopes include the following RNA molecules, synonymous codonequivalents thereof, and their DNA counterparts:

For DLGKGGNEESTKTGNAGS (SEQ ID NO: 1);GAUUUAGGUAAAGGUGGUAAUGAAGAAAGUACUAAAAC UGGUAAUGCUGGUAGU (SEQ ID NO: 6)For NPLSRKHGGPKDEE (SEQ ID NO: 2);AAUCCUUUAAGUCGUAAACACGGAGGACCGAAGGACGA GGAG (SEQ ID NO: 7).

A person skilled in the art will appreciate that there are several modesof administration available when using a composition containing anucleic acid molecule encoding an isolated ALS-specific epitope. Therecombinant molecules described above may be directly introduced intocells or tissues in vivo using delivery vehicles such as retroviralvectors, adenoviral vectors and DNA virus vectors. They may also beintroduced into cells in vivo using physical techniques such asmicroinjection and electroporation or chemical methods such ascoprecipitation and incorporation of DNA into liposomes. Recombinantmolecules may also be delivered in the form of an aerosol or by lavage.The nucleic acid molecules of the invention may also be appliedextracellularly such as by direct injection into cells.

Antibodies to disease protein epitopes, such as the ALS-specificepitopes, are prepared using techniques known in the art. For example,by using a peptide of a disease protein including a putative targetepitope, polyclonal antisera or monoclonal antibodies are made usingstandard methods. A mammal, (e.g., a mouse, hamster, or rabbit) can beimmunized with an immunogenic form of the peptide which elicits anantibody response in the mammal. Techniques for conferringimmunogenicity on a peptide include conjugation to carriers or othertechniques well known in the art.

For example, the protein or peptide is administered in the presence ofadjuvant. The progress of immunization can be monitored by detection ofantibody titers in plasma or serum. Standard ELISA or other immunoassayprocedures are optionally used with the immunogen as antigen to assessthe levels of antibodies. Following immunization, antisera can beobtained and, if desired, polyclonal antibodies isolated from the sera.

To produce monoclonal antibodies, antibody producing cells (lymphocytes)are optionally harvested from an immunized animal and fused with myelomacells by standard somatic cell fusion procedures thus immortalizingthese cells and yielding hybridoma cells. Such techniques are well knownin the art, (e.g., the hybridoma technique originally developed byKohler and Milstein (Nature 256, 495-497 (1975)) as well as othertechniques such as the human B-cell hybridoma technique (Kozbor et al.,Immunol. Today 4, 72 (1983)), the EBV-hybridoma technique to producehuman monoclonal antibodies (Cole et al. Monoclonal Antibodies in CancerTherapy (1985) Allen R. Bliss, Inc., pages 77-96), and screening ofcombinatorial antibody libraries (Huse et al., Science 246, 1275(1989)). Hybridoma cells can be screened immunochemically for productionof antibodies specifically reactive with the peptide and the monoclonalantibodies can be isolated.

Chimeric antibody derivatives, i.e., antibody molecules that combine anon-human animal variable region and a human constant region are alsocontemplated within the scope of the invention. Chimeric antibodymolecules include, for example, the antigen binding domain from anantibody of a mouse, rat, or other species, with human constant regions.Conventional methods used to make chimeric antibodies containing theimmunoglobulin variable region which recognizes disease protein epitopesof the invention (See, for example, Morrison et al., Proc. Natl Acad.Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452 (1985),Cabilly et al., U.S. Pat. No. 4,816,567; Boss et al., U.S. Pat. No.4,816,397; Tanaguchi et al., European Patent Publication EP171496;European Patent Publication 0173494, United Kingdom patent GB 2177096B).

Specific antibodies, or antibody fragments, such as, but not limited to,single-chain Fv monoclonal antibodies reactive against disease proteinepitopes are readily generated by screening expression librariesencoding immunoglobulin genes, or portions thereof, expressed inbacteria with peptides produced from the nucleic acid molecules ofdisease proteins. For example, complete Fab fragments, VH regions and FVregions are expressed in bacteria using phage expression libraries (Seefor example Ward et al., Nature 341, 544-546: (1989); Huse et al.,Science 246, 1275-1281 (1989); and McCafferty et al. Nature 348, 552-554(1990)). Alternatively, a SCID-hu mouse, for example the model developedby Genpharm, is used to produce antibodies or fragments thereof.

Antibodies specifically reactive with disease protein epitopes, orderivatives, such as enzyme conjugates or labeled derivatives, areuseful to detect disease protein epitopes in various samples (e.g.biological materials). They are useful as diagnostic or prognosticreagents and are readily used to detect abnormalities in the level ofprotein expression, or abnormalities in the structure, and/or temporal,tissue, cellular, or subcellular location of disease protein epitopes.In vitro immunoassays are also useful to assess or monitor the efficacyof particular therapies. The antibodies of the invention may also beused in vitro to determine the level of expression of a gene of apolypeptide that exists in two or more conformations such as a diseaseprotein in cells genetically engineered to produce the disease protein.

Accordingly, the invention includes isolated antibodies made using thecompositions of the invention and antibodies specific for anALS-specific epitope, wherein the ALS-specific epitope comprises anisolated peptide selected from the group consisting of:

(SEQ ID NO: 1) DLGKGGNEESTKTGNAGS; and (SEQ ID NO: 2) NPLSRKHGGPKDEE.

The antibodies are useful in any known immunoassays which rely on thebinding interaction between an antigenic determinant of the diseaseprotein epitopes and the antibodies. Examples of such assays areradioimmunoassays, enzyme immunoassays (e.g. ELISA including SandwichELISA), immunofluorescence, immunoprecipitation, latex agglutination,hemagglutination, and histochemical tests. The antibodies are useful todetect and quantify the disease protein in a sample in order todetermine its role and to diagnose the disease caused by the diseaseprotein.

In particular, the antibodies of the invention are useful inimmunohistochemical analyses, for example, at the cellular andsubcellular level, to detect a disease protein, to localize it toparticular cells and tissues, and to specific subcellular locations, andto quantitate the level of expression.

Cytochemical techniques known in the art for localizing antigens usinglight and electron microscopy to detect polypeptides such as diseaseproteins. Generally, an antibody of the invention is optionally labeledwith a detectable substance and the recognized polypeptide is localisedin tissues and cells based upon the presence of the detectablesubstance. Examples of detectable substances include, but are notlimited to, the following: radioisotopes (e.g., ³H, ¹⁴C, ³⁵S, ³²P, ¹²³I,¹²⁵I, ¹³¹I), fluorescent labels (e.g., FITC, rhodamine, lanthanidephosphors), luminescent labels such as luminol; enzymatic labels (e.g.,horseradish peroxidase, beta-galactosidase, luciferase, alkalinephosphatase, acetylcholinesterase), biotinyl groups (which can bedetected by marked avidin e.g., streptavidin containing a fluorescentmarker or enzymatic activity that can be detected by optical orcolorimetric methods), predetermined polypeptide epitopes recognized bya secondary reporter (e.g., leucine zipper pair sequences, binding sitesfor secondary antibodies, metal binding domains, epitope tags). In someembodiments, labels are attached via spacer arms of various lengths toreduce potential steric hindrance. Antibodies may also be coupled toelectron dense substances, such as ferritin or colloidal gold, which arereadily visualized by electron microscopy.

The antibody or sample may be immobilized on a carrier or solid supportwhich is capable of immobilizing cells, antibodies etc. For example, thecarrier or support may be nitrocellulose, or glass, polyacrylamides,gabbros, and magnetite. The support material may have any possibleconfiguration including spherical (e.g. bead), cylindrical (e.g. insidesurface of a test tube or well, or the external surface of a rod), orflat (e.g. sheet, test strip). Indirect methods may also be employed inwhich the primary antigen-antibody reaction is amplified by theintroduction of a second antibody, having specificity for the antibodyreactive against disease protein epitopes. By way of example, if theantibody having specificity against a polypeptide epitope such as adisease protein epitope is a rabbit IgG antibody, the second antibodymay be goat anti-rabbit gamma-globulin labeled with a detectablesubstance as described herein.

Where a radioactive label is used as a detectable substance, diseaseproteins may be localized by autoradiography. The results ofautoradiography may be quantitated by determining the density ofparticles in the autoradiographs by various optical methods, or bycounting the grains.

One embodiment of the invention is a method of detecting or diagnosingamyotrophic lateral sclerosis in a subject comprising the steps of:

-   -   (a) contacting a test sample of said subject with any one of the        antibodies of the invention, wherein the antibody binds to an        ALS-specific epitope to produce an antibody-antigen complex;    -   (b) measuring the amount of the antibody-antigen complex in the        test sample; and    -   (c) comparing the amount of antibody-antigen complex in the test        sample to a control        wherein a difference in the amount of antibody-antigen complex        in the test sample as compared to the control is indicative of        amyotrophic lateral sclerosis.

The phrase “detecting or monitoring amyotrophic lateral sclerosis”refers to a method or process of determining if a subject has or doesnot have amyotrophic lateral sclerosis or the extent of the amyotrophiclateral sclerosis. In addition, the antibodies of the invention can beused to detect or monitor the appearance and progression of SOD1aggregation, and hence progression of the disease.

The term “control” as used herein refers to a sample from a subject or agroup of subjects who are either known as having amyotrophic lateralsclerosis or not having amyotrophic lateral sclerosis. A person skilledin the art will appreciate that the difference in the amount ofantibody-antigen complex will vary depending on the control. Forexample, if the control is known to have amyotrophic lateral sclerosis,then less measurable antibody-antigen complex in the test sample ascompared to the control indicates that the subject does not haveamyotrophic lateral sclerosis or that they have less of an extent ofamyotrophic lateral sclerosis. If the control is known to haveamyotrophic lateral sclerosis, then equal or greater measurableantibody-antigen complex in the test sample as compared to the controlindicates that the subject has amyotrophic lateral sclerosis. If thecontrol is known not to have amyotrophic lateral sclerosis, then less orequal measurable antibody-antigen complex in the test sample as comparedto the control indicates that the subject does not have amyotrophiclateral sclerosis. If the control is known not to have amyotrophiclateral sclerosis, then greater measurable antibody-antigen complex inthe test sample as compared to the control indicates that the subjecthas amyotrophic lateral sclerosis.

The term “sample” as used herein refers to any fluid, cell or tissuesample from a subject which can be assayed for an ALS-specific epitope,preferably monomeric or misfolded SOD1. In one embodiment, the samplecomprises, without limitation, cerebrospinal fluid, plasma, blood serum,whole blood, spinal cord tissue, brain cells, motor neurons, a portionof the dorsal horn, or peripheral blood cells, such as erythrocytes,mononuclear cells, lymphocytes, monocytes and granulocytes.

In one embodiment of the invention, the antibodies are used to determineif monomeric or misfolded SOD1 is present in the sample. In anotherembodiment, the antibodies are labeled with a detectable marker.

In another embodiment, the epitopes are used to monitor the appearanceand titre of antibodies introduced into or raised within a recipient. Inthis embodiment, a patient sample is mixed with the epitope, andpreferably a labeled epitope, and the presence or quantity of boundantibody is determined.

Aptamers

Aptamers are also useful in the methods of the invention to detectpolypeptides such as disease proteins. Aptamers are macromolecules thatcan recognize targets such as proteins with high specificity andsensitivity.

Nucleic acid aptamers are small molecules isolated from combinatoriallibraries by a procedure named systemic evolution of ligands byexponential enrichment (SELEX) (reviewed in Cerchia L et al, FEBSLetters 528 (2002) 12-12). Using this technology aptamers that bindproteins with high target specificity and selectivity can be identified.The affinities can be comparable to antibody antigen interactions.Discrimination between native and denatured protein has been shown(Bianchini et al. Immunol Methods (2001) 252:191-97) making aptamersuseful detection agents for the methods of the invention.

Peptide aptamers, also known as paptamers, thioredoxin-insert proteinsor pertubagens are artificial proteins where an inserted peptide isexpressed on a solvent exposed surface of a structurally stable proteinwhich functions as a scaffold (Crawford M. et al. Brief Funct GenomicProteomic. 2003 April; 2:72-9). Peptide aptamers can function similarlyto antibodies and have dissociation constants that are comparable to,and sometimes better than, antibodies. They can be used to probeimmobilized proteins on nitrocellulose (Crawford M. et al. Brief FunctGenomic Proteomic. 2003 April; 2:72-9). Peptide aptamers have been shownto exhibit different affinities for small changes such as single aminoacid differences making them useful for the detection of polypeptidesthat exist in two or more conformations such as disease proteins thatexhibit different folding or aggregation conformations.

Accordingly, in one embodiment of the invention, nucleic acid and/orpeptide aptamers are used with the methods of the invention todistinguish between wild-type and disease conformation proteins. In oneembodiment the disease protein is a prion protein. In another embodimentthe disease protein is amyloid-beta. In another embodiment the diseaseprotein is tau protein. In another embodiment the disease protein isalpha-synuclein. In another embodiment the disease protein is SOD-1.

Denaturing and Disaggregation

In the methods, the polypeptide is optionally modified by denaturing thepolypeptide, for example with heat, detergent and/or chaotropic agents.The polypeptide is optionally modified by treatment with adisaggregation agent to disaggregate the polypeptide from otherpolypeptides of the same type, and from other molecules, wherein thedisaggregation agent is optionally selected from at least one of thegroup consisting of chaotropic agents, detergent and heat. Chaotropicagents can include but are not limited to such as guanidine salts, urea,and thiourea.

The inventor has shown that treating proteins with guanidinehydrochloride increases the amount of protected protein detectable.

Combining disaggregation methods can result in optimised disaggregation.For example boiling samples in sodium dodecyl sulfate (SDS; also knownas sodium lauryl sulfate) loading buffer can increase solubilization ofpolypeptides such as disease proteins, increasing the epitopes availablefor interacting with the detecting agent. For example, boiling samplesin SDS loading buffer results in enhanced solubilization, and allowsdetection of protected epitopes by sandwich ELISA. The sandwich ELISAassay system is able to identify aggregated disease protein in tissuehomogenate samples if the samples are boiled in SDS loading buffer afterperoxynitrite treatment. At peroxynitrite concentrations greater than 8mM, there is 2.5-3× as much PrP detected in the acid treated sample ascompared to the mock treated sample. Accordingly, in one embodiment thesample is boiled in SDS loading after treatment with modifying agent andbefore detection with a detecting agent such as an antibody.

Time Resolved Fluorescence (TRF) Two Point ELISA and DissociationEnhanced Lanthanide FluoroImmunoassay (DELFIA)

As previously mentioned ELISA techniques can be employed by the methodsof the invention. Time resolved flouresence two-point ELISA employingDissociation Enhanced Lanthanide FluoroImmunoassay (DELFIA) technologyis 1000 fold more sensitive than conventional ELISA techniques and canbe used with the methods of the invention to detect polypeptidesaggregated in vitro, in neural tissue of transgenic mouse models ofneurodegeneration, and in human AD, ALS, PD and LBD patient brainsamples.

The DELFIA assay uses a chelated lanthanide-labeled tracer, such aseuropium (Eu) and time-resolved fluorescence (TRF) to measure outputsignal (33). The benefit of lanthanide chelates is that theirfluorescence is intense and lasts up to 200,000 times longer thanconventional fluorophores, allowing signal capture after non-specificinterfering fluorescence has faded (particularly critical for biologicalsamples, which may possess considerable intrinsic fluorescence, theemission of which is comparatively short-lived). DELFIA-based systemscan measure as little as 100 fmol/well of Eu (33).

In one embodiment of the invention, a chemical modifying agent andantibody are employed in a sensitive capture-detection “sandwich”96-well plate DELFIA TRF system in the detection of aggregated diseasespecific proteins described herein, such as Abeta, tau, SOD1, huntingtinalpha-synuclein, islet amyloid polypeptide, resistin and p53.

A two-point EPA increases the specificity for detection of proteinssequestered in aggregates of a clinical sample. In one embodiment, twoor more chemically modifiable epitopes are present in each testpolypeptide, which would increase the specificity of diagnostic testsemploying this technology (e.g., use in two-point ELISA). In oneembodiment, the chemically modifiable epitopes are modified by the samechemical. In another embodiment, the epitopes are modified by one of twoor more different chemicals. The modified epitopes may be recognized bythe same antibody or they may be recognized by two or more differentantibodies. For clinical and commercial use, EPA must be sensitive andspecific for polypeptides aggregated in vitro and in vivo. With optimalantibodies and chemical modifying regimens, and the DELFIA-TRF systemEPA can detect 10⁵-10⁶ molecules of soluble polypeptides This maycorrespond to a single polypeptide aggregate, if these aggregates are ofsimilar size to prion protein aggregates in disease (35, 36).

Accordingly in one embodiment, the DELFIA-TRF system EPA can be used toidentify disease proteins that are in very low abundance, as low as asingle polypeptide aggregate.

Diagnostic and Screening Applications

Effective, efficient and inexpensive diagnostic and screening strategiesfor antemortem diagnosis of human neurodegenerative diseases areurgently needed, given the aging population and continued financialpressure on the health care system. EPA will achieve clinical utility bydetecting polypeptide aggregates in relevant and accessible biologicaltissues and fluids, for which no present technology exists. In oneembodiment the methods of the invention are used to diagnose individualswho have a disease protein related disease. In one embodiment, theinvention is used to diagnose individuals who have a neurodegenerativedisease. In another embodiment, the invention is used to diagnoseindividuals who have a neurodegenerative disease selected from the groupcomprising prion related diseases, AD, HD, ALS and PD. In a furtherembodiment, the methods of the invention are used post-mortem todetermine if the individual had a disease protein related disease.

The methods of the invention are used to detect whether a human has adisease protein related disease. In another embodiment, the methods areused to detect if a non-human animal has a disease protein relateddisease. In a further embodiment the non-human animal is one of thegroup comprising cattle, sheep and cervids. In another embodiment, themethods of the invention are used to detect if livestock has a diseaseprotein related disease.

In one embodiment the methods of the invention are used to detectdisease proteins in biological specimens. The biological specimens maycomprise biological fluids, such as CSF, serum, blood, tears, peritonealexudates, or urine, or tissue samples such as biopsies or brain tissue.The samples in one embodiment are antemortem samples. In anotherembodiment they are postmortem samples.

The methods of the invention are useful to quantify detection of solubleform of disease related proteins such as Abeta, tau, SOD1 huntingtin,alpha-synuclein, islet amyloid polypeptide, resistin and p53 protein.

In another embodiment, EPA is used to determine the sensitivity andspecificity of aggregate detection in homogenates from CRND8 (humanmutant APP) mouse brain and CSF (34) and G93A human mutant SOD1transgenic mice (13).

In another embodiment the invention is used to determine the sensitivityand specificity of aggregate detection in homogenates from normal(treated and untreated at low pH) and diseased frozen human brain (AD,ALS, PD, LBD).

The methods of the invention are used in one embodiment to ensurepreparations derived from mammalian blood or tissues or involvingprocesses where mammalian blood or tissues come into contact withpreparations, are free of disease proteins. In one embodiment thepreparation is a pharmaceutical product. In another embodiment thepreparation is a vaccine. In a further embodiment, the preparation is acosmetic. In one embodiment, the preparations are tested for prionproteins. In another embodiment, the preparations are tested foramyloid-beta. In another embodiment, the preparations are tested for tauprotein. In another embodiment, the preparations are tested foralpha-synuclein. In a further embodiment, the preparations are testedfor SOD-1.

In another embodiment, the methods of the invention are used to screenblood, and blood products (eg. blood fractions such as blood plasma orcompounds isolated or manufactured from blood) used for transfusions orother medical procedures for disease proteins. In another embodiment,the invention is used to screen organ transplants for disease proteins.In one embodiment, the preparations are screened for prion proteins. Inanother embodiment, the preparations are screened for amyloid-beta. Inone embodiment, the preparations are screened for tau protein. Inanother one embodiment, the preparations are screened foralpha-synuclein. In a further embodiment, the preparations are screenedfor SOD-1.

The invention is also useful for ensuring that food sources are free ofdisease proteins. In another embodiment the methods of the invention areused to test edible products derived from mammals such as meats and meatproducts; and dairy products. Foods potentially contaminated with neuraltissue (such as “mechanically separated meat,” and meat cuts containingdorsal root ganglia or other neural tissue) are particularly importantto screen for prion contamination.

Instruments that are used for invasive procedures may also be a sourceof transmitting disease. In one embodiment instruments used for medicaland surgical procedures are tested for the presence of disease proteinsusing methods of the invention. In another embodiment instruments usedfor dental hygiene are tested for the presence of disease proteins.

In a further embodiment, the invention provides methods to ensure thatdecontamination methods for removing disease proteins and diseaseprotein containing tissues, have been successful. In one embodiment themethods of the invention are used to assess decontamination proceduresin a meat processing plant. In another embodiment the methods of theinvention are used to assess decontamination in a food processing plant.In another embodiment instruments used for surgery or dentistry aretested for the presence of disease proteins.

The antibodies of the invention can be used in EPA. Thus, one aspect ofthe invention is a method of detecting whether a candidate polypeptideincluding a target epitope is in i) a wildtype conformation or ii) anon-wildtype conformation, wherein the candidate polypeptide is SOD1,and wherein the non-wildtype conformation is an aggregated form of SOD1,comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the non-wildtype        conformation, the target epitope is inaccessible and the target        epitope cannot react with the blocking agent;    -   removing unreacted blocking agent from contact with the        polypeptide;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,    -   wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        non-wildtype conformation and wherein lack of binding between        the detection agent and the target epitope indicates that the        polypeptide was in a wild type conformation, and    -   wherein the detection agent comprises an antibody specific for        an ALS-specific epitope.

Another aspect of the invention is a method of detecting whether acandidate polypeptide including a target epitope, such as SOD1, is in i)a wildtype conformation or ii) a non-wildtype conformation, comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in the        non-wildtype conformation, the target epitope is accessible and        reacts with the blocking agent, and wherein in the wildtype        conformation, the target epitope is inaccessible and the target        epitope cannot react with the blocking agent;    -   removing unreacted blocking agent from contact with the        polypeptide;    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to the target epitope that was converted from        inaccessible target epitope to accessible target epitope,    -   wherein binding between detection agent and converted target        epitope indicates that the candidate polypeptide was in a        wildtype conformation and wherein lack of binding between the        detection agent and the target epitope indicates that the        polypeptide was in a non-wildtype conformation, and    -   wherein the detection agent comprises an antibody specific for a        target epitope on SOD1 that is inaccessible to blocking agent.

Prognostic Applications

Prion protein conversion, Alzheimer's disease related polypeptide orother disease/disorder polypeptide may be periodically monitored in asubject over time (e.g. at a first time and a second time at least aweek or at least a month after the first time) to identify, for example,increased or decreased levels of PrP^(C) or increased or decreasedlevels of PrP^(Sc) in the subject. The methods of the invention are alsouseful to measure a subject's level of PrP^(C) or PrP^(Sc) to determinethe subject's response to drug therapy. Decreasing levels of prionprotein in the subject over time indicate a positive response to drugtherapy. The same methods are used with other disease or disorderprotein.

Since many neurological diseases are associated with aggregatedproteins, similar methods are useful for these diseases and theiraggregated proteins, including, but not limited to: amyotrophic lateralsclerosis (superoxide dismutase 1), Alzheimer's disease (amyloid beta),Parkinson's disease (alpha synuclein), Huntington's disease(huntingtin), cancer (p53), diabetes (eg. islet amyloid polypeptide andresistin) and other diseases involving abnormal protein folding,aggregation or post-translational modification. Such a test is useful inthe spinal fluid and other bodily fluids in addition to peripheralblood. In Alzheimer' s disease, the aggregation status of the amyloidbeta peptide is optionally monitored by determining the accessibility oftwo epitopes detected by the monoclonal antibodies 6E10 and 4G8, inaddition to other amyloid beta epitopes, using the methods described inthis application, for example, with an anti-6E10 or anti-4G8 antibody(detection agent) known in the art.

Identifying Prion Conversion Inhibitors

Since the invention is useful for detecting differences betweenpolypeptides, the invention further includes an assay for evaluatingwhether a candidate compound is capable of inhibiting or stabilizingprion conversion or formation of other disease or disorder polypeptides,such as amyloid beta, tau and APP in Alzheimer's disease, SOD1 inamyotrophic lateral sclerosis, alpha-synuclein in Parkinson's and Lewybody disease, huntingtin in Huntington's disease islet amyloidpolypeptide and resistin in diabetes and p53 in cancer. The inventionalso includes compounds for inhibiting or stabilizing prion conversion(or conversion of other disease or disorder polypeptides) identified bythe methods described in the application. Decreased protein conversionto an intermediate prion protein substrate or PrP^(Sc) (or other diseaseor disorder polypeptides shows that the candidate compound is useful fortreating prion disease.

The assays of the invention are useful to screen candidate compounds todetermine if they inhibit PrP^(Sc) formation (or formation of otherdisease or disorder polypeptides from wild type protein). Protein may becontacted with a candidate compound in vivo or in vitro and then used inthe methods of the invention to determine if wild type protein has beenconverted to PrP^(Sc) or if PrP^(Sc) has been converted to wild typeprotein. Similar methods are used with respect to other disease ordisorder polypeptides. Recombinant proteins are useful for identifyingaggregation inhibitors.

Therefore, the invention also provides methods for identifyingsubstances that inhibit conversion to PrP^(Sc) (e.g. prion proteinconversion from wild type protein or intermediate to PrP^(Sc))comprising the steps of:

-   -   reacting a polypeptide and a candidate substance, and    -   determining whether the protein has been converted to PrP^(Sc)        using the methods of the invention.

Similar methods are optionally performed to identify compounds whichstabilize the wild-type prion state, or bind to PrP^(Sc) and blockconversion of recruitable PrP isoforms.

The invention also provides methods for identifying substances thatinhibit conversion to disease or disorder polypeptides (e.g. conversionfrom wild type protein to the amyloid beta, tau or APP protein inAlzheimer's disease and other proteins and diseases described in thisapplication) comprising the steps of:

-   -   reacting a polypeptide and a candidate substance, and    -   determining whether the protein has been converted to the        amyloid betaor APP protein in Alzheimer's disease using the        methods of the invention.

Another aspect of the invention provides a method of identifyingsubstances which reverse PrP^(Sc) formation comprising the steps of:

-   -   reacting a polypeptide and a candidate substance, and    -   determining whether the PrP^(Sc) has been converted to wild type        protein using the methods of the invention.

Another aspect of the invention provides a method of identifyingsubstances which reverse amyloid beta or APP protein in Alzheimer'sdisease formation comprising the steps of:

-   -   reacting a polypeptide and a candidate substance; and    -   determining whether the amyloid beta or APP protein in        Alzheimer's disease has been converted to wild type protein        using the methods of the invention.

The same methods are used with other polypeptides associated withdiseases and disorders described in this application.

Biological samples and commercially available libraries may be testedfor substances such as proteins or small organic molecules that bind toa protein. Inhibitors are preferably directed towards specific domainsof disease proteins such as prion protein. To achieve specificity,inhibitors should target the unique sequences and or conformationalfeatures of the disease protein.

Protein Conformation Detection

The invention includes a method of detecting whether a candidatepolypeptide including a target epitope is a non-wild type conformationpolypeptide or a wild type conformation polypeptide, comprising:

-   -   contacting the candidate polypeptide with a blocking agent; and    -   determining whether the target epitope is inaccessible or        accessible to chemical modification by the blocking agent.

The accessibility or inaccessibility of the target epitope is indicativeof whether the candidate polypeptide is non-wild type conformationpolypeptide or a wild type conformation polypeptide because in one ofthe non-wild type protein and the wild type protein, the target epitopeis accessible. In the other polypeptide, the target epitope isinaccessible.

In one embodiment, the invention includes a method of detecting whethera candidate polypeptide including a target epitope is in a wildtypeconformation or a non-wildtype conformation, comprising:

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in one of        the non-wildtype conformation or the wildtype conformation, the        target epitope is accessible and reacts with the blocking agent,        and wherein in the other conformation, the target epitope is        inaccessible and does not react with the blocking agent;    -   removing unreacted blocking agent from contact with the        polypeptide (eg. by allowing blocking agent to be consumed or        degraded in the sample comprising the candidate polypeptide or        by physical or chemical removal processes);    -   modifying the candidate polypeptide to convert any inaccessible        target epitope to accessible target epitope; and    -   contacting the polypeptide with a detection agent that binds        selectively to target epitope that was converted from        inaccessible target epitope to accessible target epitope,        wherein binding between detection agent and converted target        epitope indicates that prior to conversion the candidate        polypeptide was in a conformation in which the target epitope        was inaccessible and wherein lack of binding between the        detection agent and the target epitope indicates that the        polypeptide was in a conformation in which the target epitope        was inaccessible, thereby indicating whether the polypeptide was        in a wildtype conformation or a non-wildtype conformation.

A polypeptide may have more than two conformations. For example apolypeptide may exist in a wild-type conformation, in a benignmisfolded, aggregated or otherwise non-wildtype conformation notassociated with disease, and a disease associated conformation (i.e.aggregated in higher order structures). The methods of the invention canbe applied to distinguish each of these states through the use of one ormore chemical modifying agents and/or one or more detecting agents suchas antibodies.

Detection of Intrinsically Modified Polypeptides

The invention also provides a method of detecting polypeptides thatexist in two or more conformations wherein the target epitopes in one ofthe conformations is modified by an intrinsic mechanism. The intrinsicmechanism can include intracellular and/or post-translationalmodification of a polypeptide such as phosphorylation and/orglycosylation or a modification resulting from an additive used in aprocess. The intrinsic modification blocks a target epitope obscuring itfrom detection with a detection agent. The sample of polypeptide isreacted with a blocking agent that reacts with available target epitopein polypeptide that is not intrinsically modified. The intrinsicmodification is then removed. For example if the intrinsic modificationis phosphorylation, the polypeptide is treated with a phosphatase whichremoves the phosphorylation and converts the inaccessible target epitopein the previously intrinsically modified polypeptide, to accessibleepitope. The polypeptide is then detected with a detecting agent such asan antibody.

Accordingly in one embodiment, the invention provides a method ofdetecting intrinsically modified target epitopes in a polypeptide havingtwo or more conformations comprising;

-   -   contacting the polypeptide with a blocking agent that        selectively blocks accessible target epitope, wherein in one of        the non-wildtype conformation or the wildtype conformation, the        target epitope is accessible and reacts with the blocking agent,        and wherein in the other conformation, the target epitope is        inaccessible and does not react with the blocking agent;    -   reacting the sample with an agent that removes the intrinsic        modification from the intrinsically modified polypeptide target        epitope;    -   disaggregating and/or denaturing the polypeptide in the sample;        and    -   probing with a detection agent, such as antibodies against the        target epitope, to determine whether the candidate polypeptide        is an intrinsically modified polypeptide.

In one application, the methods of the invention can be used to detectwhether polypeptides present in food items have been chemically modifiedby manufacturing processes. For example dairy products can be tested forthe presence of formaldehyde, which is used as a bacteriostatic agent.Formaldehyde formylates gamma(2) casein (Pizzano R. et al J. Agric FoodChem (2004) 52:649-54) obscuring modified epitopes from subsequentdetection by the detecting agent.

Kits

The methods described herein are optionally performed by utilizingpre-packaged diagnostic kits comprising the necessary reagents toperform any of the methods of the invention. For example, the kitstypically include at least one specific nucleic acid, peptide orantibody described herein, which are conveniently used, e.g., inclinical settings, to screen and diagnose patients and to screen andidentify those individuals expressing a disease conformation protein.Kit antibodies can comprise whole antibody, antibody fragments, singlechain antibody, monoclonal antibody and/or polyclonal antibody. The kitsoptionally also include at least one chemical agent for modifyingepitopes recognized by an antibody or aptamer. The kit is optionallybased on ELISA technology such as sandwich ELISA and DELFIA and mayemploy detergents, precipitation agents (such as phosphotungstic acid)and adsorbents typically used in ELISA technology and known to oneskilled in the art. The kit will also include detailed instructions forcarrying out the methods of the invention. Recombinant protein areuseful for standards in kits.

All such assays could be adapted and optimised to a simplehigh-throughput platform.

The following non-limiting examples are illustrative of the presentinvention.

EXAMPLES Example 1

Peroxynitrite Reacts Differently with PrP in Normal and Acid Treated orScrapie Brain Homogenate

When brain homogenate is incubated at pH 3.5 in the presence ofguanidine, PrP becomes detergent insoluble and is more susceptible tomisfolding to a PK-resistant isoform in the presence of FrP^(Sc) (29).This acid treated PrP is a ‘model prion’ which is partially misfoldedand/or aggregated resembling characteristics of PrP^(Sc). When mock (□)and acid treated () brain homogenate is incubated with increasingconcentrations of peroxynitrite and then subjected to immunoblotting,there is less PrP recognized by both 3F4 (FIGS. 1A and C) and 6H4 (FIGS.1B and D) in mock treated brain homogenate than in acid treated brainhomogenate. The PrP in the acid treated brain homogenate is protectedfrom modification by peroxynitrite.

Example 2

PrP in Scrapie Infected Hamster Brain is Protected from Modification byPeroxynitrite

The epitope protection phenomenon for ‘model prions’ as observed inexample 1 was also observed for authentic disease-misfolded prionprotein in scrapie infected hamster (Ha) brain (FIGS. 2A and B). As withmodel prions, the 3F4 and 6H4 epitopes of PrP in Ha^(Sc) brainhomogenate are protected from modification by peroxynitrite. It is clearthat ‘model prions’ and HaPrp^(Sc) share characteristics that provideprotection from chemical modification by peroxynitrite, such asdifferential misfolding or aggregation.

Example 3

Aggregation is Responsible for the Reduction in Peroxynitrite-InducedEpitope Modification of Misfolded PrP

To show that epitope protection of acid treated and scrapie brain wasdue to aggregation, samples were treated with peroxynitrite and thenincubated with or without guanidine before immunoprecipitation.Treatment of the samples with guanidine dissociates aggregates of PrP(43-45) that protect the polypeptide from modification by peroxynitrite.Incubation of mock treated brain with 2.5 M guanidine afterperoxynitrite treatment did not show an increase in 3F4 and 6H4 epitopesas revealed by immunoprecipitation (FIG. 3A lanes 1-4). However, whenperoxynitrite-treated acid brain homogenate was incubated withguanidine, there was an increase in PrP that could be detected byimmunoprecipitation with 3F4 and 6H4 immunobeads (FIG. 3A lanes 5-8).This shows that guanidine is able to dissociate aggregates of acidtreated brain homogenate and release PrP that is protected frommodification by peroxynitrite. Other means of solubilizing PrPaggregates were used and boiling samples in SDS loading buffer resultedin the greatest observed solubilization to date.

Example 4

Optimization of EPA Parameters

Titration experiments with peroxynitrite, hydrogen peroxide andmethylene (based on UV light photolysis of the precursor diazirine) orother modifying agents, identify the optimal conditions for epitopeprotection in:

1. Normal hamster and human brain “model prions”, using immunoblottingand conventional fluorescence ELISA.

2. Infectious prions from hamster and human brain, using immunoblottinganalysis and time-resolved fluorescence

In each case, brain homogenates are prepared and mixed with increasingconcentrations of the modifying agent and processed as described(immunoblotting, and time resolved fluorescence). This defines the typeand concentration of chemical agent allowing the maximal distinctionbetween monomeric and aggregated prion proteins. Additional informativecontrol experiments include using recombinant hamster PrP^(C) in bufferand in PrP knockout mouse brain, and by mouse normal andscrapie-infected brain (murine PrP is 6H4+ and 3F4−).

In some cases, infectious prions may have different properties forchemical modification than do “model prions,” and brain prions maydisplay different chemical modification properties than do endogenousprions circulating in blood, or FrP^(Sc) detectable in urine of infectedanimals. One of skill in the art shall readily identify the optimalconditions for authentic endogenous prions using known techniques.

Example 5

EPA Adapted to a Fluorescent ELISA System

The epitope protection assay for aggregated PrP was adapted to afluorescent sandwich ELISA system using 6H4 as the capture antibody and3F4 as the detection antibody (FIG. 3B). The sandwich ELISA assay systemis able to identify aggregated PrP in acid treated brain homogenate butonly if the samples are boiled in SDS loading buffer after peroxynitritetreatment. At peroxynitrite concentrations greater than 8 mM, there is2.5-3× as much PrP detected in the acid treated sample as compared tothe mock treated sample.

Example 6

Detection of a Single Brain Prion

A single brain prion has been estimated to comprise 10⁵-10⁶ molecules ofPrP^(Sc). Detection of 10⁸-10⁹ molecules of recombinant PrP usingconventional fluorescence ELISA has been accomplished. The assay used isabout 1000-fold more sensitive for single-prion detection—the necessarysensitivity is provided by the Dissociation enhanced lanthanidefluoroimmunoassay (DELFIA). DELFIA uses a chelated lanthanide-labeledtracer, such as europium (Eu) and time-resolved fluorescence (TRF) tomeasure output signal. The benefit of lanthanide chelates is that theirfluorescence duration is 200,000 times longer than conventionalfluorophors, allowing signal capture after non-specific interferingfluorescence has faded (particularly critical for biological samples,which may possess considerable non-specific fluorescence). DELFIA-basedsystems can measure as little as 100 fmol/well of Eu which is >1000times more sensitive than conventional ELISA assays, which detectssingle prions by EPA. The optimal TRF 96-well plate reader for theDELFIA system is manufactured by Wallac-Victor (Perkin-Elmer), and isused to automate sample analysis.

Using an optimal chemical modifier and optimal conditions a sensitivecapture 96-well plate assay for detection of hamster and human prions,using the DELFIA TRF system is provided. This is used to:

-   -   1. Characterize, optimize and quantify detection of recombinant        prion protein by TRF.    -   2. Determine the sensitivity of the DELFIA-TRF for hamster and        human brain prions.

Example 7

Detection of Prion Proteins in Biological Fluids

The EPA achieves commercial utility by detecting PrP^(Sc) in biologicaltissues and fluids for which no present technology exists. Blood prionsare in very low abundance (10-100 prions/mL by bioassay, andprotease-resistant PrP in urine is only intermittently/sporadicallydetectable by precipitation of large fluid volumes. Also, anyprospective blood test must contend with high concentrations of PrP^(C)(10⁶-fold more than PrP^(Sc)) and “blocking” by heterologous plasmaproteins. Using the optimized chemical modification regimen and theDELFIA-TRF system, the sensitivity thresholds for EPA in blood and urineare determined using:

-   -   1. Hamster and human plasma and urine “spiked” with a titration        of 263K hamster prions;    -   2. Plasma and urine from Syrian hamsters “endogenously” infected        with 263K prion disease

Biological fluids clinically accessible by non-invasive routes provide asubstrate for a practical antemortem test for diagnosis and screening ofprion infection in humans and animals. The methods of this invention mayalso be used in post-mortem testing. One of skill in the art readilydetermines whether EPA with “prion spike” titration in normal blood andurine reveals similar DELFIA-TRF signals to the same prion titration inbuffer, showing that the EPA is not affected by “blocking factors” inthese biological fluids. Interestingly, preferential “blocking” ofFrP^(Sc) by heterologous proteins may actually enhance epitopeprotection to chemical modifying agents. If decreased detection ofprions in blood or urine is observed, pre-clearing strategies arereadily employed to enhance FrP^(Sc) detection with detergents,precipitating agents, and adsorbents typically used in commercial ELISAassays which are known to one skilled in the art.

Human and bovine plasma and urine and other bodily fluids are testedusing optimized EPA conditions and compared to samples from humanvariant CJD and BSE, respectively. Although the monoclonal antibody 6H4recognizes PrP from all relevant species, other antibodies (commerciallyavailable) are used for the DELFIA TRF system for cattle, sheep, andcervids, which lack the 3F4 epitope. Other antibodies and epitopesuseful in methods described in this application will be readily apparentto those of skill in the art.

Example 8

Detection of Aggregated Amyloid Beta (Abeta) Using EPA

Amyloid beta peptide (Abeta) is a normal cleavage product of theproteolytic processing of amyloid precursor protein (APP). Abetaaccumulates in discrete plaques in affected regions of Alzheimer'sdisease brain, and triggers neuronal death and gliosis observed in thisdisease. Plaque Abeta is aggregated and rich in beta-sheet structure, incontrast to the Abeta region of APP expressed by normal cells. Usingepitope protection technology, it was demonstrated that the 6E10 epitopein the Abeta region of APP is less accessible to peroxynitritemodification in Alzheimer's disease brain compared to normal brain (FIG.4 panel A). Similarly, the 6E10 epitope is partially protected in brainhomogenates that have been treated at low pH to induce proteinaggregation (FIG. 4 panel B). Abeta 1-42 peptide aggregated by overnightincubation at 1 mg/ml in water shows prominent epitope protection of the6E10 epitope to peroxynitrite modification, in comparison with solublenon-aggregated Abeta 1-42 (FIG. 4 panel C). A further example of thisphenomenon is presented in FIG. 4, panel D which shows normal (◯) andaggregated () Abeta 1-42 treated with increasing concentrations ofperoxynitrite, subjected to immunoblotting with 6E10 antibody.

The 6E10 epitope of APP is also unavailable to peroxynitritemodification in AD brain homogenates and in normal brain homogenatesaggregated by low pH, but normal untreated brain does not show thisprotection (FIG. 4 panel A and B), showing molecular interaction in vivoof APP with an Abeta-domain blocking molecule (perhaps Abeta itself;ref. 9).

The sensitive and specific EPA detection of aggregated Abeta inbiological fluids (such as blood and spinal fluid), or protection ofAbeta epitopes in APP in cells and tissues, provides an antemortemdiagnostic test for Alzheimer's disease. The methods of the inventiondescribed in this application are used for this diagnostic test.

Detection of Aggregated Tau Protein by EPA

Dying neurons release intracellular proteins such as tau into the CSF(39) and likely ultimately blood. Tau studies are directly performed onbrain specimens including Alzheimer patient samples and control brain.

Example 9

Detection of Aggregated Superoxide Dismutase 1 (SOD1) by EPA

SOD1-containing cytoplasmic inclusions are detected in many diseasedmotor neurons from familial and sporadic ALS patients (15), and in mosttransgenic mouse (16, 17) and tissue culture models (18) of the disease.Human SOD1 can be aggregated in vitro. Further SOD1 is modifiable bysuccinic anhydride and DEPC. This property can be exploited by EPAtechnology to discriminate between aggregated and unaggregated SOD1protein.

Purified SOD1 from human erythrocytes (Sigma) was aggregated in ametal-catalyzed oxidation reaction. Soluble SOD1 was treated withvarying concentrations of DEPC, denatured with heat, and immunoblottedwith anti-SOD1 antibodies. Western blotting shows that increasingconcentrations of DEPC are associated with decreases in antibody bindingin soluble SOD1 (FIG. 5) showing that sites are available formodification by a blocking agent.

Antibodies against SOD1 selected a priori for utility in EPA are used todistinguish disease specific aggregated SOD1 from wildtype SOD1.Relevant factors include:

-   -   1) selecting an epitope on the molecular surface of the native        dimer to be accessible to chemical modification in the native        soluble state;    -   2) identifying a linear epitope to optimize detection in the        denatured state on immunoblots and ELISA;    -   3) immunogenicity;    -   4) uniqueness to SOD1; and    -   5) presence of acidic amino acids (Glu and Asp) that are readily        modified by epoxides.

The five SOD1 sequences that meet these criteria are: 22QKESNG27 (SEQ IDNO:8); 51EDNTAGCTSA60 (SEQ ID NO:9); 74PKDEERHV81 (SEQ ID NO:10);89ADKDG93 (SEQ ID NO:11); and 127GKGGNEQSTK136 (SEQ ID NO:12) (in bold:solvated side chains).

Additionally the electrostatic loop sequence and zinc binding loop ofhuman SOD1 are surface-accessible sequences and are involved inaggregate formation (Elan, J. et al. Nature Structural Biology (2003)10:461-67).

These sequences are:

Electrostatic loop of human SOD1: (SEQ ID NO: 1)Asp Leu Gly Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Ala Gly SerZinc-binding loop of human SOD1: (SEQ ID NO: 2)Asn Pro Leu Ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu

Example 10

Detection of Aggregated alpha-synuclein by EPA

Most cases of Parkinson's disease are sporadic, but both sporadic andfamilial forms of the disease are characterized by intracellular Lewybodies in dying neurons of the substantia nigra, a population ofmidbrain neurons (˜60,000) that are selectively decimated in PD. Lewybodies are predominantly composed of alpha-synuclein (22). Mutations inthe gene encoding alpha-synuclein have been found in patients withfamilial Parkinson's disease (reviewed in 23). Another gene associatedwith autosomal recessive PD is parkin, which is involved inalpha-synuclein degradation (22, 23). Diffuse cortical Lewy bodiescomposed of alpha-synuclein are observed in Lewy body disease (LBD), adementing syndrome associated with Parkinsonian tone changes,hallucinations, and rapid symptom fluctuation (24).

The Syn-1 epitope is optionally blocked by chemical modification ofrecombinant alpha-synuclein with DEPC (histidine reactive), andalpha-synuclein aggregated in vitro is partially protected from DEPCepitope blocking (FIG. 6).

Aggregated alpha-synuclein in vitro is protected from modification byDEPC whereas normal protein is not. Three mg/mL mutant A53Talpha-synuclein was incubated at 37° C. for three days for aggregation.The aggregation reaction was applied to ultracentrifugation. Normalprotein prior to aggregation (containing soluble alpha-synuclein) andthe pellet resuspension from the ultracentrifugation (containinginsoluble alpha-synuclein) were treated with varying concentrations ofDEPC, denatured with heat, and blotted with Syn-1 antibody from BDBiosciences. FIG. 6A shows that increasing concentrations of DEPC areassociated with a gradual decrease in antibody binding in normalalpha-synuclein. Insoluble alpha-synuclein shows little change inantibody binding with increasing concentrations of DEPC until the DEPCconcentrations reach 1 mM. A graphical representation of these findingsis presented in FIG. 6B. The extent of antibody binding to DEPC-treatednormal alpha-synuclein (▪) decreases gradually overall but more rapidlyat higher concentrations of DEPC. Insoluble alpha-synuclein (▴), on theother hand, shows little change in the extent of antibody binding. Thelast data point at 0.01M DEPC for insoluble alpha-synuclein increasesdue to the darkening of the film.

Example 11

Detection of Aggregated Proteins in CSF

Extracellularly deposited Abeta has been quantified in CSF and blood ofpatients with AD and normal controls (6-8). Intracellular neuronalproteins, such as alpha-synuclein, have been detected in CSF and blood(37, 38). Dying neurons release intracellular proteins 14-3-3,neuron-specific enolase, tau, and alpha-synuclein into the CSF (39), andlikely ultimately blood. A proportion of released protein in disease isin an aggregated form. EPA technology is applied to determine theproportion of polypeptide aggregates in CSF samples from patients withAD, ALS, PD, and LBD. Signal is measured for polypeptides disaggregatedbefore and after chemical treatment, representing “total” and“protected” epitopes, respectively, to determine the proportion ofpolypeptide in the aggregated state. Using the optimized mAbs andchemical modification regimens, and the DELFIA-TRF system, EPAsensitivity is determined in:

-   -   1. Normal CSF “spiked” with polypeptides aggregated in vitro.    -   2. CSF from patients with AD, ALS, PD, and LBD.

The proportion of aggregated polypeptides in a CSF sample, is determinedeven if it constitutes only 10⁵-10⁶ molecules. Detergents, precipitatingagents (such as phosphotungstic acid), and adsorbents typically used incommercial ELISA assays to enrich for relevant species are optionallyemployed. Biological fluids clinically accessible by non-invasive routesprovides an ideal substrate for a practical antemortem test fordiagnosis and screening of neurodegenerative diseases.

Materials and Methods

Materials

Recombinant hamster PrP (rhaPrP) and 6H4 was from Prionics. Recombinanthuman PrP (rhuPrP) was from Roboscreen. Biotin-3F4 and 3F4 were fromSignet. 3F4 reacts against MKHM (SEQ ID NO:3) and 6H4 reacts againstDYEDRYYRE (SEQ ID NO:4). 6E10 anti-Abeta (from Signet) reacts againstEFRHDS (SEQ ID NO:5) (residues 3-8).

Other antibodies and the epitopes recognized if known, are provided intable 1 above.

Preparation of Acid-Misfolded PrP and APP

Acid misfolded PrP was used as “model prions” in this study and wasprepared as in (29). Briefly, 100 μl of 10% brain homogenate was mixedwith an equal volume of 3.0 M GdnHCl (final concentration 1.5 M) in PBSat pH 7.4 or pH 3.5 adjusted with 1 N HCl, followed by rotation at roomtemperature. After 5 h incubation, samples were methanol precipitatedwith 5 volumes of ice-cold methanol and pellets were resuspended in 100μl of lysis buffer. The samples treated at pH 7.4 were designated asmock-treated samples.

Peroxynitrite Treatment of Brain Homogenates

An aliquot (18 μl) of normal or misfolded/diseased brain homogenate wasvortexed while 2 μl of peroxynitrite in 100 mM NaOH/60 mM H₂O₂ was addedto give a final peroxynitrite concentration of 0-15 mM. After vortexingfor a further 15 s, the samples were subjected to Western blotting,immunoprecipitation or sandwich ELISA.

DEPC Treatment of Erythrocyte SOD1

Purified SOD1 from human erythrocytes (Sigma) is aggregated in ametal-catalyzed oxidation reaction consisting of 40 μM SOD1, 4 mMascorbic acid, and 0.2mM CuCl₂ in 10 mM Tris-acetate buffer (pH7) at 37°C. for three days. Ultracentrifuged supernatant (containing solubleSOD1) and the pellet resuspension (containing insoluble SOD1) aretreated with varying concentrations of DEPC (100 pM to 0.1 M), denaturedwith heat, and immunoblotted with anti-SOD1.

Western Blotting

Samples were boiled in SDS loading buffer (62 mM Tris (pH 6.8), 10%glycerol, 2% SDS, 5% beta-mercaptoethanol and 0.01% bromphenol blue) for5 min. and separated on 12% Tris-Glycine polyacrylamide gels followed bytransfer to Hybond-P. PrP was detected using 3F4 (1:50000) 6H4 (1:10000)or 6E10 (1:1000) as the primary antibodies and HRP-conjugated goatanti-mouse (1:10000) as the secondary antibody followed by exposure toECL-Plus and visualization by exposure to Kodak X-OMAT film. Bandintensities were quantitated using UnScan-IT software.

Immunoprecipitation

Samples were incubated with 50 μl of Ab-conjugated (100 μg/ml) DynalM-280 magnetic beads in a final volume of 1 ml binding buffer (3% NP-40;3% Tween-20) for 3 h at room temperature with rotation. Beads werewashed in wash buffer (2% NP-40; 2% Tween-20) ×3 and boiled in 30 μl SDSloading buffer without beta-mercaptoethanol for 5 min. Supernatants wereanalyzed by Western blotting as described above.

Sandwich ELISA

The capture antibody (6H4; 1:5000 in 50 mM bicarbonate binding buffer,pH 9.6) was bound to an opaque 96-well plate (Nunc Maxisorp) byovernight incubation at 4° C.

After blocking with 1% BSA in 0.05% TBST for 2 h, plates were washed 3×in TBST and incubated overnight at 4° C. with standard concentrations ofrhuPrP or rHaPrP along with unknown brain homogenates. Plates werewashed 3× and incubated with the detecting antibody biotin-3F4 (1:5000)at RT for 1 h. After washing 3×, avidin-HRP (1:5000) was added andincubated for 30 min. at RT. Following a final wash step (×3) the platewas developed with Quantablu fluorescent substrate for 10-90 min at RTand fluorescent intensities determined with an excitation of 325 nm andemission of 420 nm.

Example 12

Antibody Production

An ALS-specific epitope (DLGKGGNEESTKTGNAGS) (SEQ ID NO:1) bearing anN-terminal Cys residue was conjugated to KLH for immunization of Balb/cmice, and BSA for ELISA screening. Multiple immune injections were donefor each projects at 21-day internal. The adjuvant for first injectionwas Complete Freund's Adjuvant (Sigma, Cat#F5881-6×10 mL), andIncomplete Freund's Adjuvant (Sigma, Cat#F5506-6×10 mL) for the rest ofthe boosts. The test bleeds were collected at day 7-10 after the 3rdinjection. The cell fusion was done 3-4 days later after the final boostwithout any adjuvant.

The fusion partner used was Sp 2/0-Ag14 (ATCC#CRL-1581). The fusionbetween fusion partner SP2/0 and spleen cells was done at 1:5 ratio(2.0×10⁷: 1.0×10⁸) and 1 ml pre-warmed PEG (MW1450: Sigma, Cat#P7181)was added. Fusion cells were re-suspended into 50 ml of DMEM with 10%FBS and plated into 5 96-well plates at 100 μl/well. 100 μl/well of 2×HAT DMEM medium was added after fusion cells growing in normal mediumfor 24 hours. Medium was changed on day 5 and 7 with fresh 1× HATmedium. On day 10-12, 50 μl of supernatant was picked from each well forfirst ELISA screening. Cherry-picking on same day, positive clones weretransferred to 24 well plates. Antibody supernatants were screened byELISA with both specific antigen and non-related antigen upon cellsconfluence in 24-well plates. Positive clones were transferred to 6-wellplates for expansion or subcloning. The subcloning was done by limitingdilution at 50-70 cells/96-well plate.

For large scale antibody production, 0.2-0.5 ml of Pristane (Sigma,Cat#T-7640) or IFA was injected to each mouse (Balb/c) by i.p. forpriming. On day 7-14, 500,000 to 5,000,000 hybridoma cells in 0.5 ml 1×PBS at log phase were injected to each mouse by i.p. The ascitic fluidwas build up within 1-2 weeks. 2-5 ml of ascites can be tapped from eachmouse, and the IgG concentration around 1-9 mg/ml. Protein A was used todo the IgG2 and 3 purification, and Protein G for IgG1.

The IgG mAb clone was designated 10E11C11. This antibody displaysproperties consistent with its recognition of a disease-specific epitopefor monomeric or misfolded SOD1. This mAb binds to denatured SOD1 onimmunoblot membranes, recognizing monomeric denatured SOD1(unstructured). The mAb does not recognize the dimeric SOD1 onimmunoblotting. On immunoprecipitations mediated by 10E11C11 conjugatedmagnetic beads, there is no detectable binding of native SOD1 fromnormal human brain or mouse brain and spinal cord. The mAb doesefficiently immunoprecipitate SOD1 deliberately misfolded by low pH, thechaotrope guanidine, or both. Most importantly, 10E11C11 efficientlyimmunoprecipitates misfolded SOD1 in a mouse model of ALS caused bytransgenic overexpression of mutant SOD1 (G93A). Notably, mouseendogenous SOD1 present in the same tissue is not immunoprecipitated,suggesting that the misfolded human mutant SOD1 does not “co-recruit”normal mouse SOD in this disease model.

Antibodies were also raised in a like manner to the epitopeNPLSRKHGGPKDEE (SEQ ID NO:2), bearing an N-terminal Cys residue.

The antibodies are readily available and can be obtained from NeilCashman at the Brain Research Centre, UBC Hospital, 2211 Wesbrook Mall,Vancouver, British Columbia, V6T 2B5, Canada (neil.cashman@utoronto.ca).

While the present invention has been described with reference to whatare presently considered to be the preferred examples, it is to beunderstood that the invention is not limited to the disclosed examples.To the contrary, the invention is intended to cover variousmodifications and equivalent arrangements included within the spirit andscope of the appended claims.

All publications, patents and patent applications, including U.S.application No. 60/496,381 (entitled Methods of Detecting Prion Protein(Cashman & Lehto), filed on Aug. 20, 2003 and U.S. application No.60/497,362 (entitled Epitope Protection Assay (Cashman & Lehto), filedon Aug. 21, 2003 and the Corresponding Canadian applications nos.2,437,675 and 2,437,999 as well as U.S. Ser. No. 12/236,731 filed onSep. 24, 2008 and PCT/CA2004/001503 filed on Aug. 20, 2004 are hereinincorporated by reference in their entirety to the same extent as ifeach individual publication, patent or patent application wasspecifically and individually indicated to be incorporated by referencein its entirety.

REFERENCES

1. Prusiner S B. Shattuck lecture—neurodegenerative diseases and prions.N Engl J Med. 344:1516-26, 2001.

2. Caselli R J. Current issues in the diagnosis and management ofdementia. Semin Neurol. 23:231-40, 2003.

3. Cashman N R. Do the benefits of currently available treatmentsjustify early diagnosis and announcement? Arguments for. Neurology.53(Suppl 5):550-2, 1999.

4. Selkoe D J. Alzheimer's disease: genes, proteins, and therapy.Physiol Rev. 81:741-66, 2001.

5. Puglielli L, Tanzi R E, Kovacs D M. Alzheimer's disease: thecholesterol connection. Nat Neurosci. 6:345-51, 2003.

6. Mehta P D, Pirttila T, Mehta S P. Plasma and cerebrospinal fluidlevels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. ArchNeurol. 57:100-5, 2000.

7. Clark C M, Xie S, Chittams J et al. Cerebrospinal fluid tau andbeta-amyloid: how well do these biomarkers reflect autopsy-confirmeddementia diagnoses? Arch Neurol. 60:1696-702, 2003.

8. Green A J. Cerebrospinal fluid brain-derived proteins in thediagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease.Neuropathol Appl Neurobiol. 28:427-40, 2002.

9. Lorenzo A, Yuan M, Zhang Z, et al. Amyloid beta interacts with theamyloid precursor protein: a potential toxic mechanism in Alzheimer'sdisease. Nat Neurosci. 3:460-4, 2000.

10. Rosen D R, Siddique T, Patterson D. et al. Mutations in Cu/Znsuperoxide dismutase gene are associated with familial amyotrophiclateral sclerosis. Nature. 362:59-62, 1993.

11. Deng H X, Hentati A, Tainer J A et al. Amyotrophic lateral sclerosisand structural defects in Cu,Zn superoxide dismutase. Science.20;261:1047-51, 1993.

12. Anderson, P M in Brown R H, Meininger V, Swash eds. AmyotrophicLateral Sclerosis. London: Martin Dunitz. 2000.

13. Gurney, M. E., Pu, H., Chiu, A. Y., et al. Motor neuron degenerationin mice that express a human Cu,Zn superoxide dismutase mutation.Science 264:1772-1775, 1994.

14. Ripps, M. E., Huntley, G. W., Hof, P. R., et al. Transgenic miceexpressing an altered murine superoxide dismutase gene provide an animalmodel of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A 92:689-693, 1995.

15. Kato, S., Takikawa, M., Nakashima, K., et al. New consensus researchon neuropathological aspects of familial amyotrophic lateral sclerosiswith superoxide dismutase 1 (SOD1) gene mutations: inclusions containingSOD1 in neurons and astrocytes. Amyotroph. Lateral. Scler. Other MotorNeuron Disord. 1: 163-184, 2000.

16. Bruijn, L. I., Becher, M. W., Lee, M. K. ALS-linked SOD1 mutant G85Rmediates damage to astrocytes and promotes rapidly progressive diseasewith SOD1-containing inclusions. Neuron 18: 327-338, 1997.

17. Bruijn, L. I., Houseweart, M. K., Kato, S., Aggregation and motorneuron toxicity of an ALS-linked SOD1 mutant independent from wild-typeSOD1. Science 281: 1851-1854, 1998.

18. Durham, H. D., Roy, J., Dong, L., and Figlewicz, D. A. Aggregationof mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS.J. Neuropathol. Exp. Neurol. 56:523-530, 1997.

19 Li Y K, Chir J, Chen F Y. Catalytic mechanism of a family 3beta-glucosidase and mutagenesis study on residue Asp-247. Biochem J.355(Pt 3):835-40, 2001.

20 Rose R B, Rose J R, Salto R, Craik C S, Stroud R M. Structure of theprotease from simian immunodeficiency virus: complex with anirreversible nonpeptide inhibitor. Biochemistry 32:12498-507, 1993.

21. Olanow C W. The scientific basis for the current treatment ofParkinson's disease. Annu Rev Med 55:41-60, 2004.

22. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis ofParkinson's disease. J Neurol 250 Suppl 3:11111-4, 2003.

23. Eriksen J L, Dawson T M, Dickson D W, Petrucelli L Caught in the ac:alpha-synuclein is the culprit in Parkinson's disease. Neuron 40:453-6,2003.

24. McKeith I, Mintzer J, Aarsland D et al. Dementia with Lewy bodies.Lancet Neurol 3:19-28, 2004.

25 Alvarez B, Ferrer-Sueta G, Freeman B A, Radi R. Kinetics ofperoxynitrite reaction with amino acids and human serum albumin. J BiolChem 274:842-8, 1999.

26. Alvarez B, Radi R Peroxynitrite reactivity with amino acids andproteins. Amino Acids 25:295-311, 2003.

27. Sokol P P, Holohan P D, Ross C R. Arginyl and histidyl groups areessential for organic anion exchange in renal brush-border membranevesicles. J Biol Chem 263:7118-23, 1988.

28. Zou W-Q, Yang D-S, Fraser P E, Cashman N R, Chakrabartty A.All-or-none fibrillogenesis of a prion peptide. Europ J Biochem268:4885-4891, 2001.

29. Zou W-Q, Cashman N R. Acidic pH and detergents enhance in vitroconversion of human brain PrPC to a PrPSc-like form. J Biol Chem277:43942-43947 2002.

30. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi X-F, Crow J,Cashman N R, Kondejewski L H, Chakrabartty A. Oxidation-inducedmisfolding and aggregation of superoxide dismutase and its implicationsfor amyotrophic lateral sclerosis. J Biol Chem 277:47551-62002, 2002.

31. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, ZouW-Q, Estey L A., Kondejewski L H, Francoeur G P, Papadopoulos M,Haghighat A, Spatz S J, Tonelli Q, Ledebur H C, Chakrabartty A, CashmanN R. A PrPSc-specific immunological epitope. Nature Medicine 9:893-9,2003.

32. Rakhit R, Crow J P, Lepock J R, Kondejewski L H, Cashman N R,Chakrabartty A. Monomeric Cu/Zn superoxide dismutase is a commonmisfolding intermediate in the oxidation models of sporadic and familialALS. J Biol Chem e-pub Jan 2004.

33. MacGregor, I., Hope, J., Barnard, G. Application of a time-resolvedfluoroimmunoassay for the analysis of normal prion protein in humanblood and its components. Vox Sang 77:88-96, 1999.

34. Chishti M A, Yang D S, Janus C et al. Early-onset amyloid depositionand cognitive deficits in transgenic mice expressing a double mutantform of amyloid precursor protein 695. J Biol Chem 276:21562-70, 2001.

35. Bolton D. C., McKinley M. P., and Prusiner S. B. Identification of aprotein that purifies with the scrapie prion. Science 218:1309-1311,1982.

36. Beekes M., Baldauf E., and Diringer H. Sequential appearance andaccumulation of pathognomic markers in the central nervous system ofhamsters orally infected with scrapie J. Gen. Virol 77:1925-1934, 1996.

37. Borghi R, Marchese R, Negro A, et al. Full length alpha-synuclein ispresent in cerebrospinal fluid from Parkinson's disease and normalsubjects. Neurosci Lett. 287:65-7, 2000.

38. El-Agnaf O M, Salem S A, Paleologou K E, et al. Alpha-synucleinimplicated in Parkinson's disease is present in extracellular biologicalfluids, including human plasma. FASEB J 17:1945-7, 2003.

39. Verbeek M M, De Jong D, Kremer H P. Brain-specific proteins incerebrospinal fluid for the diagnosis of neurodegenerative diseases. AnnClin Biochem 40(Pt 1):25-40, 2003.

40. Coulthart, M. B. and Cashman, N. R. (2001) CMAJ. 165, 51-58

41. Prusiner, S. B. (1998) Proc. Natl. Acad. Sci. U.S.A 95, 13363-13383

42 Will, R. G., Ironside, J. W., Zeidler, M., Cousens, S. N., Estibeiro,K., Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A., and Smith, P.G. (1996) Lancet 347, 921-925.

43. Kocisko, D. A., Lansbury, P. T., Jr., and Caughey, B. (1996)Biochemistry 35, 13434-13442.

44, Barnard, G., Helmick, B., Madden, S., Gilbourne, C., and Patel, R.(2000) Luminescence. 15, 357-362.

45. Meyer, R. K., Oesch, B., Fetzer, R., Zurbriggen, A., and Vandevelde,M. (1999) J. Virol. 73, 9386-9392.

46. Kang, S. C., Li, R., Wang, C., Pan, T., Liu, T., Rubenstein, R.,Barnard, G., Wong, B. S., and Sy, M. S. (2003) J. Pathol. 199, 534-541.

47. Shaked G M, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R.(2001) J Biol Chem. 276, 31479-82.

48. Ross C A et al. Nature Medicine, (2004) S10-17.

49. Davies S W et al Cell 90, 537-548 (1997).

50. Scherzinger E et al. Proc. Natl. Acad. Sci. USA 96, 4604-9, (1999).

51. Sen Set al Protein Sci. (2003) 12:953-962.

52. Llewelyn C A et al. Lancet (2004) 363:417-421.

53. Peden A H et al. Lancet (2004) 364:527-529.

54. Andreoletti O et al. Nat. Med. (2004) 6:591-593.

55. Thomzig A et al. J Clin Invest. (2004) 10:1465-72.

56 Glatzel M et al. N Engl J Med. (2003) 349:1812-20.

57 Bosque P J et al. Proc Natl Acad Sci USA. (2002) 99:3812-7.

We claim:
 1. A method of detecting or diagnosing amyotrophic lateralsclerosis in a subject comprising the steps of: (a) contacting a testsample of said subject with an antibody specific for an ALS-specificepitope, wherein the ALS-specific epitope is selected from the groupconsisting of: DLGKGGNEESTKTGNAGS; and NPLSRKHGGPKDEE

to produce an antibody-antigen complex; (b) measuring the amount of theantibody-antigen complex in the test sample; and (c) comparing theamount of antibody-antigen complex in the test sample to a control;wherein a difference in the amount of antibody-antigen complex in thetest sample as compared to the control is indicative of amyotrophiclateral sclerosis.
 2. The method of claim 1, wherein the antibody isspecific for DLGKGGNEESTKTGNAGS.
 3. The method of claim 1, wherein theantibody is specific for NPLSRKHGGPKDEE.
 4. The method according toclaim 1, wherein the antibody is monoclonal, polyclonal, chimeric orhumanized.
 5. The method according to claim 1, wherein the antibody isan antibody fragment.
 6. The method according to claim 5, wherein theantibody fragment is a Fab, Fab′, F(ab′)₂, scFv, dsFv, ds-scFv, dimers,minibodies, diabodies, or multimers thereof or bispecific antibodyfragments.
 7. A kit for diagnosing amyotrophic lateral sclerosisaccording to the method of claim 1 comprising an antibody specific foran ALS-specific epitope, wherein the ALS-specific epitope comprises anisolated peptide selected from the group consisting of:DLGKGGNEESTKTGNAGS; and NPLSRKHGGPKDEE;

and instructions for the use thereof.
 8. The kit according to claim 7,wherein the antibody is specific for DLGKGGNEESTKTGNAGS.
 9. The kitaccording to claim 7, wherein the antibody is specific forNPLSRKHGGPKDEE.
 10. The kit of claim 7 further comprising a recombinantpeptide standard.
 11. The kit of claim 10 wherein the standard is anisolated peptide selected from the group consisting of:DLGKGGNEESTKTGNAGS; and NPLSRKHGGPKDEE.


12. A diagnostic agent comprising (1) an antibody specific for anALS-specific epitope, wherein the ALS-specific epitope comprises anisolated peptide selected from the group consisting of:DLGKGGNEESTKTGNAGS; and NPLSRKHGGPKDEE;

attached to (2) a label that produces a detectable signal, directly orindirectly.
 13. A diagnostic according to claim 12, wherein the antibodyis specific for DLGKGGNEESTKTGNAGS.
 14. A diagnostic according to claim12, wherein the antibody is specific for NPLSRKHGGPKDEE.
 15. Thediagnostic agent of claim 12, wherein the label comprises aradioisotype, a fluorescent compound, a chemiluminescent compound, anenzyme, an imaging agent or a metal ion.
 16. A kit comprising thediagnostic agent of claim 12 and instructions for the use thereof.